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ABSTRACT 
 
Endemic circulation of hepatitis E virus (HEV) in Namibia was suspected from 
serological data during an outbreak of non-A non-B hepatitis in Rundu, in 1995. The 
source of the outbreak was surmised to be the water supply, which had been 
compromised approximately six months earlier. This study examines nucleotide and 
amino acid sequence data obtained from the open reading frame 2 (ORF2) region towards 
the carboxy terminal end (3’-end) of the HEV genome extracted from the stool of 
Namibian patients infected during this outbreak. The overall aim is to establish a 
polymerase chain reaction (PCR) for molecular diagnosis of HEV, to isolate HEV from 
specimens collected from acute viral hepatitis outbreaks such as this one in Namibia, to 
characterize, at the genomic level, the strain of the virus involved, to compare the strain 
to those involved in other outbreaks of HEV in southern Africa and to relate this 
information to available data from other parts of the world. A nested reverse 
transcriptase-polymerase chain reaction (RT-PCR) was developed for molecular 
diagnosis of HEV and four representative HEV isolates from this outbreak have been 
successfully amplified, sequenced and analysed over a 451 base pair (bp) region of a 
subgenomic fragment from the 3’-end of the genome in ORF2. Phylogenetic analysis 
showed the four Namibian HEV isolates clustered with a Mexican isolate in genotype II 
and shared a 85.8-86.3 percent (%) nucleotide identity with the 1987 Mexican isolate but 
were only 77.6-79.6 % similar to other African isolates. HEV isolated from the same 
region of Namibia in 1983 was reported to cluster into genotype I and this analysis 
clearly indicates the difference between the strains involved in the two outbreaks. Virus 
from sporadic cases of HEV isolated in 1997/8 in Nigeria were also found to be from 
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genotype II. This is the first study performed in South Africa to isolate, amplify by PCR 
and sequence the HEV. It is also the first to characterize HEV as the causative agent of 
the hepatitis outbreak that occurred in Namibia in 1995. As it reports the presence of a 
second unique HEV strain in southern Africa, we conclude that HEV genotypes may be 
more widely distributed than previously thought. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Discovery and history of the hepatitis E virus 
 
Hepatitis E was not recognized until the early 1980s when sensitive and specific tests for 
antibody to hepatitis A virus (HAV) were first applied to the study of epidemic 
waterborne hepatitis in India, all of which had, in the past, been thought to be caused by 
the hepatitis A virus (Wong et al., 1980). Direct experimental evidence for an additional 
waterborne hepatitis agent was first reported in 1983 when Balayan et al. (1983) 
described the successful faecal-oral transmission of hepatitis to a volunteer from patients 
with hepatitis A-like disease in Tashkent, Uzbekistan. The volunteer, who had been 
infected with HAV in the past, developed severe clinical hepatitis 36 days after ingestion 
of a faecal suspension from the patients but did not have a serological response to HAV 
or hepatitis B virus (HBV). He did, however, develop antibodies to virus-like particles 
(VLPs) which were recovered from his faeces on days 28 and 45 post-exposure and 
determined by immune electron microscopy (IEM) to be 27 to 30 nanometres (nm) in 
diameter (Purcell, 1996). 
 
This form of non-A, non-B hepatitis was referred to as epidemic non-A, non-B hepatitis, 
or enterically-transmitted non-A, non-B (ET-NANB) hepatitis, and the agent of the 
disease was subsequently found to be the major cause of sporadic hepatitis cases in 
regions where the epidemic form was known to exist (Khuroo et al., 1983; Arankalle et 
al., 1993). IEM and primate transmission studies remained the only means of studying 
ET-NANB hepatitis until 1990 when Reyes et al. succeeded in cloning and sequencing a 
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part of the genome of the virus. The agent was renamed hepatitis E virus (HEV; Reyes et 
al., 1990) and its first full genome sequence was reported by Tam et al., (1991). 
 
A significant proportion of acute viral hepatitis occurring in young to middle-aged adults 
in Asia, Africa and the Indian subcontinent is now recognized to be caused by HEV. 
Hepatitis E has been shown to occur in both epidemic and sporadic endemic forms and is 
primarily associated with the ingestion of faecally contaminated drinking water. The first 
documented case of hepatitis E involved an outbreak of 29,000 cases of icteric hepatitis 
in New Delhi, India, in 1955 which followed widespread faecal contamination of the 
city’s drinking water (Bradley, 1994). Both this and a similar epidemic of viral hepatitis 
which occurred between December 1975 and January 1976 in Ahmedabad city, India, 
also due to contaminated water supplies, were concluded to be caused by hepatitis E after 
retrospective serological analysis of paired serum specimens showed the aetiological 
agent to be neither HAV nor HBV. 
  
Careful review of records and other related documents and manuscripts by Bradley, 
during a visit to the former Union of Soviet Socialist Republics (USSR), showed that the 
epidemiological and clinical features of the large hepatitis epidemics observed in the 
Kirgiz Republic, USSR, between 1955 to 1956, were remarkably similar to those 
associated with the 1955-56 New Delhi outbreak. During these outbreaks 10,800 cases of 
acute viral hepatitis were documented in young to middle-aged adults and approximately 
18 % of infected pregnant women died (Bradley, 1994). Although these outbreaks were 
never described in the western scientific literature, Bradley concluded that HEV was the 
most likely aetiological agent.  
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Figure 1.1 Electron micrograph of typical 
32nm virus particles recovered from stool of a 
case of ET-NANB occurring in Telixtac, 
Mexico, during a 1980 outbreak. Particles are 
morphologically indistinguishable from those 
recovered from cases in Borneo, Burma, India, 
Somalia and Tashkent (adapted from Bradley, 
1992). 
1.2 The hepatitis E virus 
 
 1.2.1 Classification and morphology 
 
The virus has a non-enveloped icosahedral particle that was originally described as a 
spherical 27 to 30 nm particle (Balayan et al., 1983), although in subsequent studies this 
diameter reportedly varies from 32 to 34 nm (Purcell, 1996; Krawczynski et al, 2000). 
HEV has been grouped with the Caliciviridae, a family of small, round-structured viruses 
(Figure 1.1), which includes agents associated with nonbacterial gastroenteritis in 
humans and animals (Reyes, 1997). However, the phylogenetic position of HEV, by 
analysis of non-structural genes, is outside the caliciviruses (Berke and Matson, 2000) 
and HEV remains taxonomically unclassified (Fauquet and Pringle, 1999). The 
morphological features of HEV are similar to those of Norwalk virus and both have a 7.5 
kilobase (kb) single-stranded, positive sense RNA genome which contains three open 
reading frames (ORFs; Bradley, 1994). However, although the sequence of HEV is 
related to Norwalk virus, it most closely resembles the sequences of Rubella virus, 
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currently classified as a Togavirus and Beet necrotic yellow vein virus, a plant Furovirus 
(Fry et al., 1992). In addition, codon usage most closely resembles that of Rubella virus 
(Tam et al., 1991). It has thus been proposed that, on the basis of genetic relatedness and 
genomic organization, the taxonomy of positive sense RNA viruses should be 
reorganized (Koonin and Dolja, 1993). Under such a scheme, Rubella virus, Beet 
necrotic yellow vein virus and HEV would be placed in separate but related families 
(Purcell, 1996).  
 
On the basis of morphology, HEV cannot be reliably distinguished from other “small 
round viruses” found in faeces (Purcell, 1996). HEV appears to be substantially different 
from Picornaviruses including HAV (Irshad, 1999). However, based on hybridization 
experiments, IEM and immunoflourescence blocking studies, HEV has been found to be 
the single major agent responsible for the majority of ET-NANB hepatitis cases seen 
worldwide. 
 
 1.2.2 Genomic organization 
 
The cloning of HEV (Krawczynski and Bradley, 1989a; Reyes et al., 1990; Yarbough et 
al, 1991) was followed by the sequencing of its genome (Tam et al., 1991; Tsarev et al., 
1992). Molecular analysis of the HEV genome has shown that it is a positive sense, 
single stranded RNA of approximately 7.5 kb in length with short 5' and 3'-noncoding 
regions. The RNA codes at least three separate ORFs and there is little variation among 
different isolates.  
  
The putative nonstructural genes are located at the 5' end of the HEV genome and the 
structural genes are located at the 3' end (Figure 1.2; Irshad, 1999). The first open reading 
frame (ORF1) begins 28 nucleotides (nt) from the 5' end and extends for 5,079 base pairs 
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Figure 1.2 Genomic organization of HEV (adapted from Irshad, 1999). 
(bp) ending at nucleotide 5,107. The 5' untranslated region (27 bp) is thought to play a 
role in transcription and expression of the virus. Analysis of the nucleotide sequence of 
the Burmese isolate revealed the presence of consensus sequences in ORF1 which encode 
both an RNA-dependent RNA polymerase (RdRp) and an RNA helicase. These are 
located at the extreme carboxy-terminal portion of the ORF1 poly-protein. A methyl 
transferase has been found located at the amino-terminal of the polyprotein which is a 
strong indication that HEV is capped (Zhang et al., 2001). Other domains in ORF1 
include a ‘Y’ domain of unknown function, a putative papain-like cysteine protease 
domain and an ‘X’ domain of unknown function, acting as a flexible hinge (Figure 1.3). 
ORF1 thus appears to encode the nonstructural proteins with enzymatic activities.  
 
Open reading frame 2 (ORF2) which is located at the 3' end of the RNA molecule begins 
at nucleotide 5,147 and extends for 1,980 bps terminating 65 bps upstream of the poly 
(A) tail  (Irshad, 1999). This ORF encodes the structural proteins. These include a 660 
amino acid glycosylated protein used in transport and a polypeptide with a high 
percentage of basic amino acids. Major immunological epitopes have been identified in 
this reading frame (Irshad, 1999). 
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The smallest ORF, ORF3, is located at the end of ORF1 between, and partially 
overlapping, the other two reading frames (Irshad, 1999). It encompasses 369 bps and 
overlaps the first ORF1 at its 5' end by one nucleotide only whereas the 328 bps at its 3’ 
end overlap the 5’ end of ORF2. The function of the proteins encoded by ORF3 are still 
unknown. One of these encodes a protein 123 amino acids long which has an 
immunoreactive epitope at its carboxy-terminus and a transmembrane sequence at its 
amino-terminus. 
 
  
  
Figure 1.3 Genome map of the hepatitis E virus open reading frames (ORFs). 
The putative function of the genes contained in ORF1 is shown in the shaded boxes 
and the legend at the bottom of the figure. ORF2 is assumed to contain the 
structural gene(s) of HEV. A putative signal sequence at the amino-terminus of the 
ORF2 peptide is denoted by a shaded box at the amino end of ORF2. The inverted 
Ys denote potential glycosylation sites. The function of ORF3 is unknown but its 
carboxyl half is hydrophilic and contains epitopes recognized by antibodies from 
patient sera. Its amino half contains two hydrophobic regions separated by a small 
hydrophilic segment. The first hydrophobic region at the amino-terminal end of 
ORF3 terminates with a poly-cysteine region and the second hydrophobic region 
may be a transmembrane sequence. M, methyl transferase; Y, domain Y; Pr, 
papain-like cysteine protease; P, proline ‘hinge’; X, domain X; H, helicase; R, RNA 
replicase (adapted from Purdy et al., 1993).   
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 1.2.3 Physiochemical properties 
 
The buoyant density of hepatitis E viral antigen and/or virus particles have been reported 
to be 1.35g/cm3 (Balayan et al., 1983) and 1.39 to 1.40g/cm3 in CsCl (Favorov et al., 
1989) while others have found the virus to be labile in CsCl (Bradley et al., 1987). The 
buoyant density of HEV is 1.29g/cm3 in potassium tartrate and glycerol (Bradley, 1990). 
The sedimentation coefficient of HEV is 183s (Bradley, 1992). HEV is unstable when 
stored at temperatures between -70 °C and +8 °C and readily degrades when freeze-
thawed but it is stable in liquid nitrogen (Bradley et al., 1987). Hepatitis E virions appear 
to be unaltered by exposure to triflourotrichloroethane (Ticehurst, 1991). Survival of 
HEV in the intestinal tract suggests that the virus is relatively stable in acid and mild 
alkaline conditions (Purcell, 1996). 
  
1.3 The natural history of  HEV  
 
 1.3.1 Course and clinical features of infection  
 
On August 31, 1990, Chauhan deliberately infected himself with HEV prepared from the 
stool of a patient involved in an epidemic of ET-NANB hepatitis and recorded the course 
and clinical features of the disease (Chauhan et al., 1993). Anicteric hepatitis 
accompanied by epigastric pain and discoloured urine began 30 days post-inoculation 
(average 40 days, ranges to 60 days; www.cdc.gov). The icteric phase started on day 38 
and lasted until day 120. This was accompanied by a rise in serum alanine 
aminotransferase (ALT) and bilirubin. Stools collected on day 34 and 37 showed 
characteristic VLPs and transmitted disease to three monkeys. The stools first became 
positive for HEV reverse transcription-polymerase chain reaction (RT-PCR) with onset 
of the icteric phase on day 38 and remained positive until the ALT activity peaked on day 
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46. Illness resulted in severe nausea and vomiting. HEV was first observed in serum on 
day 22 before the symptoms of hepatitis developed and persisted during the pre-icteric 
phase, declined during the icteric phase and had disappeared by the time ALT peaked on 
day 46. The HEV antibody first appeared on day 41 and persisted for the duration of this 
study. Two years after the transmission IgG anti-HEV was still present in this individual. 
A distinctive feature of disease in this volunteer was the unusually long phase of 
abnormal serum ALT, lasting about three months, in contrast to two to three weeks in 
monkeys. The volunteer recovered completely and follow-up over two years has shown 
no further clinical or biochemical evidence of liver disease. The course of HEV infection 
in laboratory infected primates (Figure 1.4) follows a very similar pattern to that 
described by Chauhan although the immune response appears late in the incubation 
period or during the acute phase of the illness (Tsarev et al., 1992). Not all HEV 
infections are clinically apparent although the majority of clinical cases in epidemics 
experience jaundice, anorexia and hepatomegaly (Purcell, 1996). Approximately half of 
the cases experience abdominal pain and tenderness, nausea, vomiting and fever. Like 
hepatitis A, hepatitis E never progresses to chronicity.  
 
To better characterize HEV infections, viremia, faecal shedding and antibody responses 
to HEV infections were examined in 67 patients with acute markers for hepatitis E who 
were admitted to the Infectious Disease Hospital in Kathmandu, Nepal in 1993 (Clayson 
et al., 1995). In this study day zero refers to the onset of symptoms and therefore 
correlates with day 30 of the initial study outlined above. It was found that the proportion 
of RNA-positive sera increased from day zero to day three and day 8 to 11 in the 
presence of decreased ALT activity (Figure 1.4) suggesting an uncoupling of viral 
replication and liver injury. 
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Figure 1.4 Changes in viremia, faecal shedding, IgM and IgG to HEV, and serum alanine 
aminotransferase (ALT) activity at various days after onset of illness. Numbers of faecal 
and serum samples examined for each time period are listed at the top of figure (adapted 
from Clayson et al., 1995).  
One possible explanation is that HEV virions may be released from hepatocytes by a 
mechanism other than cell lysis as in Poliovirus and Simian virus 40 (Kallman et al., 
1958; Clayson et al., 1989). Another possibility is that virus detected in serum after the 
decrease in ALT activity was released after replication in tissue(s) other than the liver. 
HEV antigens were previously detected in the cytoplasm of cells in the small intestine, 
spleen and lymph nodes of rats and swine experimentally infected with HEV, suggesting 
that HEV replicates in these cells (Corcoran et al., 1993; Maneerat et al., 1996). Perhaps 
HEV replicates in tissues other than the liver in humans as well. At least initially the 
period of viremia was found to coincide with the period of IgM and IgG responses to 
HEV infection (Clayson et al., 1995). The detection of prolonged viremia in the presence 
of antibodies raises the possibility that acute-phase immunoglobulin may lack 
neutralizing activity.  
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In one report, protracted viremia of 45 to 112 days duration was detected by PCR in 
approximately one-fourth of patients presenting with acute sporadic hepatitis E (Reyes, 
1997). A prolonged period of virus shedding in faeces (to day 52) was also seen in one 
patient from whom samples were available. These findings indicate that protracted 
viremia my be more common in hepatitis E than previously thought and may contribute 
to prolonged infectivity and endemicity in the community. In another report, serum 
samples were obtained from four boys aged 5 to 10 years diagnosed with acute hepatitis 
in Egypt (Schlauder et al., 1993). For all four patients, the first sample drawn two to 
three days after onset of symptoms was PCR positive for HEV RNA while the samples 
obtained 10 to 20 days after onset of illness were negative. These results show that HEV 
does not produce a persistent viremia in all the patients.  
 
 1.3.2 Pathogenesis 
 
Because serologic and molecular tests for HEV were developed only recently, the 
pathogenesis of HEV is poorly understood as outlined in paragraph 1.3.1 above. 
However, Purcell (1996) summarizes the data and reaches some speculative conclusions 
as shown in Figure 1.5. Entry of the virus into the host is believed to be primarily by the 
oral route via contaminated water. The site of primary replication is not known but is 
presumed to be in the intestinal tract. It is not clear how the virus reaches the liver but it 
is presumably via the portal vein. It replicates in the cytoplasm of hepatocytes and is 
released into the bile and blood.  
 
Reyes (1997) reports that the key pathologic features of HEV include “cholestatic 
hepatitis, proliferation of bile ductules and pseudoglandular arrangement of hepatocytes 
surrounding distended bile canaliculi with frank parenchymal necrosis. The complete 
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Figure 1.5 Diagrammatic illustration of the clinical and serologic events in a typical case of 
acute hepatitis E. Antibody pattern is depicted as measured by ELISA. Viremia and faecal 
shedding patterns are based on PCR data (adapted from Purcell , 1996). 
pathologic picture includes mild portal and lobular inflammation with a predominantly 
polymorphonuclear leukocyte and macrophage infiltration.” 
 
Lau et al. (1995) detected the HEV genome in 50 to 60 percent of hepatocytes of two 
patients with fulminant hepatitis E. Viral transcript and antigens were found to be in the 
cytoplasm of infected cells exclusively, consistent with viral cytoplasmic replication 
(Reyes, 1997). The presence of a minimal inflammatory infiltrate was consistent with the 
hypothesis that the majority of the hepatic injury associated with HEV fulminant 
hepatitis is due to a direct cytopathic mechanism rather than to a host-mediated immune 
injury. Cytopathic effects in vitro have also been observed (Huang et al., 1992). 
 
HEV is implicated in fulminant hepatitis on only a sporadic basis (Lau et al., 1995). Pre-
existing conditions may contribute to fulminant hepatic failure (Reyes, 1997). In one case 
HEV-associated fulminant hepatic failure developed in a 6-year-old patient with 
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Wilson’s disease (Sallie et al., 1994). The patient developed progressive deterioration in 
liver function with serum, liver and bile all positive for HEV by RT-PCR. 
 
The case fatality rate of hepatitis E infection varies in different reports but an overall rate 
of one to three percent exists which is high when compared to 0.2 percent for hepatitis A 
(www cdc.gov). The mortality of hepatitis E in pregnancy increases with each succeeding 
trimester and may reach 20 percent (Purcell, 1996). In experimentally infected rhesus 
monkeys, the HEV incubation period in pregnancy may be considerably shortened but 
the disease is not necessarily more severe (Arankalle et al., 1993). In this study, none of 
the pregnant animals developed fulminant hepatitis, but there was apparent transmission 
to one of three infants as well as a macerated foetal still-birth.  
 
In a vertical transmission study, six of ten pregnant women presenting with hepatitis E 
developed fulminant hepatic failure (Khuroo et al., 1995). PCR on cord blood or early 
birth samples from the infants showed five with detectable HEV sequences and elevated 
ALT levels. This study clearly establishes intrauterine infection with HEV as a 
significant cause of perinatal morbidity and mortality (Reyes, 1997). Premature 
deliveries with a high infant mortality (33 %) have also been reported (Purcell, 1996). 
 
 1.3.3 Diagnosis 
 
Viral antibody or the presence of VLPs in clinical specimens was in the past detected by 
IEM using specimens from infected animals or humans. Solid phase immune electron 
microscopy (SPIEM) analysis was also used as another IEM method to detect VLPs in 
the bile of infected monkeys and in human stools (Chauhan et al., 1994). Fluorescent 
antibody blocking assay is another microscopy method used to screen sera for total 
immunoglobulin to HEV. This assay measures the ability of serum to block binding of a 
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fluorescein isothiocyanate (FITC)-labeled antibody probe to native HEV antigens in liver 
sections from experimentally inoculated monkeys (Clayson et al., 1995). Another 
blocking assay uses HEV recombinant antigens as blocking reagents to inhibit anti-HEV 
from binding to the solid phase antigen made from polystyrene beads coated with 
synthetic peptides (Dawson et al., 1992). It was later realized that IEM was not practical 
due to low levels of virus excretion in faeces (Reyes, 1997). The estimated titre of HEV 
in stool is 100-fold less (estimated by PCR) than that seen with HAV. Purification of a 
presumed viral-specific antigen containing fractions from faecal specimens was the basis 
for one of the earliest diagnostic tests (Sarthou et al., 1986). These tests were problematic 
because of the variability and difficulty in standardizing reagents. Assays of this sort 
have been largely supplanted by the ability to detect viral-specific nucleic acid by PCR 
(Reyes, 1997)  and agarose gel electrophoresis.  
 
Enzyme-linked immunosorbent assay (ELISA) is now the preferred screening method for 
large-scale seroprevalence studies. ELISAs based on recombinant antigens and synthetic 
peptides are commercially available for HEV. Both open reading frames 2 and 3 of the 
HEV genome encode major immunogenic epitopes at their carboxyl-termini that are 
immunoreactive with sera from infected animals or humans (Yarbough et al., 1991). The 
prototype HEV ELISA used the ‘3-2’ derived ORF2 protein and the ‘4-2’ derived ORF3 
protein from the HEV Mexico and HEV Burma strains, respectively, expressed in 
Escherichia coli (E. coli). Another commonly used ELISA is the Abbott HEV ELISA 
(Abbott GmbH Diagnostica, Wisbaden, Germany) assay which uses two recombinant 
antigens ‘SG-3’ from ORF2 and ‘8-5’ the full length of ORF3 from the Burmese strain 
expressed in E. coli and coated on polystyrene beads (Christensen et al., 2002). Current 
tests are capable of detecting IgM anti-HEV in up to 90 percent of acute infections if a 
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serum sample is obtained one to four weeks after onset of disease (Bryan et al., 1994). 
By three months, IgM anti-HEV is no longer detectable in 50 percent or more of hepatitis 
E cases (Arankalle et al., 1994). IgM anti-HEV reaches peak titers of 1:1,000 to 1:10,000 
during the first four weeks after onset of hepatitis. IgG anti-HEV peaks in titer (1:1,000 
to 1:100,000) between two and four weeks after onset of hepatitis and diminishes 
relatively rapidly thereafter (Purcell, 1996). A more recent assessment of the diagnostic 
value of commercial IgG and IgM anti-HEV ELISA tests (manufactured by Genelabs 
Diagnostics) compares the sensitivity (86.7 and 53.3 %, respectively) and specificity 
(92.1 and 98.6 %, respectively) of these tests using serum samples taken from patients 
with HEV RNA detected by RT-PCR tests (Lin et al., 2000) and concludes that they 
provide a good diagnostic screening test for acute hepatitis E even in nonendemic areas. 
 
The cDNA, RNA and protein, hybridization diagnostic methods appeared to be more 
sensitive for detecting HEV than standard IEM (Balayan, 1993). These methods include 
Southern blot hybridization (Ray et al., 1991; Turkoglu et al., 1996), Northern blot 
hybridization (Tam et al., 1991) and a sensitive and specific western blot assay for both 
IgM and IgG anti-HEV. The latter has been shown to be capable of detecting anti-HEV 
in acute and convalescent phase sera (Krawczynski et al., 1989b; Favorov et al., 1992; 
Hyams et al., 1992; El-Zimaity et al., 1993). 
 
1.4 Host range  
 
Labrique et al. (1999) debated the possibility of a zoonotic reservoir of HEV. Wild-
caught primates have occasionally been found to have anti-HEV IgG before laboratory 
inoculation. Antibodies to HEV have also been found in domestic swine, cows, sheep, 
goats, chickens and water buffaloes. The serum of 44 to 94 % of wild rats captured from 
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different regions of the United States (US) contained antibodies to a human strain of 
HEV (Kabrane-Lazizi et al., 1999). These animals are not limited to antibody reactivity; 
in Nepal, HEV RNA and anti-HEV were found to be highly prevalent in domestic swine 
(Clayson et al., 1995). Wild rodents captured in the Kathmandu Valley of Nepal were 
also found to harbour HEV RNA with nucleotide sequences similar to those of human 
strains from that area. Of particular interest as a reservoir in the US is domestic swine. A 
novel virus was identified in 1997 in the US domestic swine population and was 
designated “swine HEV” (HEV-S; Meng et al., 1997). This virus, which is commonly 
present in domestic swine older than three months, was found to have nucleotide 
sequences (79-85 %) and amino acid sequences (77-92 %) that were closely related to 
those of some human HEV strains. In fact, the US-1 (human) strain is genetically more 
similar to the swine HEV (> 97 % nucleotide identity in ORF1 and ORF2) than to other 
human strains of HEV (Meng et al., 1998; Schlauder et al., 1998). Swine HEV is also 
serologically cross-reactive with human HEV. Inoculation of nonhuman primates with 
this swine variant caused infection. While Labrique et al. (1999) speculate whether swine 
HEV circulates or causes illness in humans and whether human HEV has an animal 
reservoir, Karetnyi et al. (1999) presented evidence of possible interspecies transmission 
(see paragraph 1.5.4). 
 
While chimpanzees have been shown to be susceptible to infection with HEV, only two 
isolates, from Ahmedabad, India and Telixtac, Mexico, have been shown to cause liver 
disease in this host (Bradley, 1994). Intravenous inoculation of chimpanzees with other 
isolates proven by IEM to contain HEV, including those from Burma, USSR (Tashkent) 
and Nepal, have not caused disease in these animals. These results suggest that 
adaptation can occur in at least one host species and that some isolates of HEV may be 
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more virulent than others.  
 
1.5 Transmission of HEV 
 
HEV has relatively low infectivity, with a secondary attack rate of about 2 % among 
household contacts (Bradley et al, 1991). HEV is believed to have a lower environmental 
stability, which may result in decreased secondary transmission. Furthermore, a larger 
infective dose may be necessary to cause overt disease among contacts of HEV patients  
(Labrique et al., 1999) and nosocomial spread has been reported in South Africa (see 
paragraph 1.5.3 below). Also accidental transmission of HEV in the laboratory has been 
reported; one Calcutta outbreak involved 21 people in a research facility where HEV was 
being studied. (Neogi et al., 1995). 
 
No secondary cases of hepatitis have been reported among sexual partners of cases under 
conditions of epidemic or sporadic disease (Longer et al., 1993; Myint et al, 1985). 
However a high incidence of HEV antibodies was found in a small study of homosexual 
men in Italy (33/162 or 20.4 %. Montella et al., 1994). The higher prevalence of HEV 
found among homosexual men indirectly confirms the role of transmission through the 
faecal-oral route facilitated by sexual practices.  
 
Vertical transmission of HEV from mothers to their infants has been reported, with 
associated morbidity and mortality (as discussed in paragraph 1.3.2 above). 
 
Outbreak investigations reveal faecally contaminated drinking water as the major source 
of HEV and although transmission in developed countries is discussed below, the causes 
outlined ultimately equate to faecally contaminated water. 
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 1.5.1 Contaminated drinking water 
 
HEV infection is common in many tropical and subtropical hot climate countries 
including India, Nepal, Myanmar, Pakistan, Afghanistan, Borneo, China, Mexico, North 
Africa (Egypt and Algeria in particular), East Africa (Djibouti, Somalia, Ethiopia and 
Sudan), West Africa (Ivory Coast) and, more recently, southern Africa (Botswana and 
Namibia). Many of the  epidemics both large and small are associated with sewage 
contaminated drinking water such as the 1955 outbreak in New Delhi in which 30,000 
cases were reported (Viswanathan, 1957) and the Chinese outbreak with greater than 
100,000 cases in the Xinjiang Uighar region (Zhuang et al., 1991). 
 
Adult anti-HEV seroprevalence rates of 4 to 11 % have been reported in various 
developing countries such as China (Lee et al., 1994), Turkey (Thomas et al., 1993), 
Venezuela (Pujol et al., 1994) and South Africa (Grabow et al., 1994). However, since 
none of the anti-HEV positive individuals had a record of clinical viral hepatitis which 
could be related to HEV infection they would appear to be sporadic cases of sub-clinical 
infection (Grabow et al., 1996). A study by Tucker et al. (1996) suggests that 
contaminated water may play a major role in the spread of HEV in South Africa. In this 
study the prevalence of anti-HEV was determined among 407 urban and 360 rural black 
South African adults living in formal housing, squatter camps or mud huts in the Western 
Province. Rural subsistence farmers living in isolated clusters of traditional mud huts 
who use unchlorinated river water were found to be at greatest risk (17.4 %) of HEV 
infection. Rural people living in formal housing within villages had a significantly 
reduced risk in comparison (5.3 %). However, there was no difference in prevalence 
between the urban formal and squatter communities despite poor living conditions within 
the majority of squatter areas where non-water-borne sewerage disposal methods are 
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used. Urban squatter communities do, however, unlike their rural equivalents, rely 
entirely on chlorinated tap water for domestic use. 
 
 1.5.2 Transmission in developed or non-endemic areas 
 
Non-endemic areas, corresponding to industrialized nations, are considered to be free of 
natural foci of HEV infection and HEV is thus regarded as unimportant since only rare 
sporadic cases are reported. However seroprevalence of 0.4 to 3.2 % has been described 
in the general population of developed countries (Moaven et al., 1995; Lavanchy et al., 
1994). 
 
  1.5.2.1 Sewage polluted shellfish 
 
 It is suspected that in Mediterranean countries, such as Italy and Spain, cases of HEV 
infection could be causatively related to the consumption of shellfish cultivated in 
sewage-polluted waters (Balayan, 1993). 
 
  1.5.2.2 Travelling 
 
Most sporadic cases of HEV disease which have been reported in Westerners who 
develop jaundice occur shortly after their return from endemic areas. A seroprevalence 
study of 104 selected sera from sporadic cases of non-A, non-B, non-C (NANBNC) 
hepatitis encountered in metropolitan areas of the former southern Transvaal province of 
South Africa during 1993 found only five HEV positive reactors (Swanepoel et al, 1996). 
Three of these sera reacted weakly (OD < 1.000), whereas two sera, from patients who 
had visited the Indian subcontinent, reacted strongly (OD > 1.000).  
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 1.5.3 Nosocomial transmission  
 
Robson et al. (1992) relate a case study in which a 34-year-old woman from Cape Town 
presented at 32 weeks gestation at the maternity unit of Groote Schuur Hospital with 
diarrhoea, jaundice and episodic confusion. She had recently returned from holiday in 
Bombay, India. She also had a history of contact with hepatitis in India. Samples taken at 
the onset of illness were tested for antibodies to HEV (anti-HEV) and shown to contain 
both IgG and IgM anti-HEV by western blotting. Six weeks after attending this patient, 
the referring physician and two theatre sisters from the maternity unit, attended the liver 
clinic with features compatible with acute self-limiting viral hepatitis. Serum from one 
theatre sister, taken six weeks after exposure, was positive for anti-HEV-IgG and -IgM. 
There was no serological evidence of HEV infection in the physician or the other theatre 
sister though they may have had very low grade HEV infection which could not be 
confirmed serologically by antibody tests. The mode of transmission of HEV in these 
cases was presumptive. The physician had helped the patient from a bedpan, while the 
nurses had transferred the confused, unco-operative patient to the operating theatre for 
repair of vaginal lacerations. Thus all had been exposed to blood and stool. Hepatitis E 
must be suspected in travellers returning from the Indian subcontinent and appropriate 
care taken especially since pregnant women with acute hepatitis E infection may progress 
to severe fulminant hepatitis.  
 
 1.5.4 Interspecies transmission 
 
Recently, HEV-like virus was isolated from swine in Iowa (Karetnyi et al., 1999). Swine 
production is a major industry in Iowa with the potential for human exposure to swine in 
and around industrial and family farm operations. One study with the objective to 
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determine whether individuals in Iowa are exposed to HEV was undertaken (Karetnyi et 
al., 1999). Anti-HEV prevalence in four selected Iowa populations was determined. Sera 
were collected from 204 patients with NANBNC hepatitis; 87 staff members of the 
Department of Natural Resources (DNR); 332 volunteer blood donors in 1989 and 111 
volunteer blood donors in 1998. All sera were tested for anti-human HEV IgM and IgG 
by ELISA. Both the patients with NANBNC hepatitis (4.9 %) and the healthy field 
workers from the Iowa DNR (5.7 %) showed significantly higher prevalence of anti-HEV 
IgG compared to normal blood donor sera collected in 1998. It was concluded that 
human HEV circulates in Iowa. At risk human populations with occupational exposure to 
wild animals and environmental sources of domestic animal wastes have increased 
seroprevalence of HEV antibodies. These findings support the presence of endogenous 
HEV in the United States and raises the possibility of interspecies transmission. 
  
 1.5.5 Parenteral transmission  
 
Although HEV infection frequently results in subclinical infection and does not lead to 
chronicity, transfusion of HEV-positive blood to hepatitis B surface antigen (HBsAg) 
carriers, pregnant women or persons with ongoing replication of other hepatitis viruses, 
can result in fulminant hepatic failure leading to death (Arora et al., 1996). It is because 
95 % of HEV infections remain subclinical (Arankalle et al., 1995) and viremia persists 
for at least two weeks prior to serum alanine amino-transferase (ALT) changes  (Chauhan 
et al., 1993) and HEV has a predilection for young adults, a population which 
corresponds to eligible blood donors, that the possibility of viremic blood being 
transfused is not remote, particularly in a region of high endemicity.  
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Arankalle and Chobe (1999) found 1.5 % of a group (N = 200) of voluntary blood donors 
in India to be HEV RNA positive. This study also showed that a significantly higher 
proportion of blood donors older than 20 years of age had prior exposure to HEV (22.7 
%) as opposed to those under 20 years of age (9.8 %). Interestingly, 76 % of the paid 
plasma donors tested (N = 71) were found to be anti-HEV IgG positive. The higher 
exposure of the plasma donors to HEV was not related to poor living conditions as had 
been found in commercial blood donors (N = 191) and infection may have resulted from 
contamination of the plasmapheresis machine. Although Tsarev et al. (1997) found the 
HEV titre to be at least 1000-fold lower in serum than in faeces and HEV has been 
shown to be unstable at +4 oC, these results indicate a possible risk of transfusion-
associated hepatitis E in hyper-endemic areas, particularly if transfusion is immediate 
(Chobe et al., 1997).  
 
Three percent (2/66) of injecting drug users (IDU) were found to contain HEV antibodies 
in a small study in Italy to determine other risk factors (Montella et al., 1994). With 
regard to IDUs, HEV could be transmitted in this population group through injection or 
ingestion of contaminated drugs, even though direct person-to-person contact because of 
poor hygiene cannot be ruled out. 
  
1.6 Prevention and control 
 
 1.6.1 Prevention 
 
Environmental factors are a major contributor to the endemic and epidemic spread of 
HEV. Management of the community outbreak involves identification and correction of 
the environmental factors promoting faecal contamination of drinking water. Seasonal 
monsoons can lead to floods that can overwhelm water treatment facilities leading to 
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contaminated drinking water (Reyes, 1997). The correction of inadequate water treatment 
facilities is essential. Consideration should be given to protecting pregnant women from 
potential sources of infection in an epidemic situation. Simple hand-washing procedures 
should suffice to interrupt any person-to-person transmission. 
 
In outbreak settings, the handling and disposal of human waste must follow strict sanitary 
guidelines (Drabick et al., 1997). In sporadic cases, the patients’ excreta must be 
disposed of hygienically, with care being taken to avoid contact with these waste 
products. Improvements in drinking water storage, treatment and distribution should be 
encouraged as a means of reducing HEV transmission. Better community sanitation and 
sewage management would also reduce rates of HEV infection worldwide, especially in 
flood-prone areas.  
 
Health education about personal and environmental hygiene in high-risk communities 
might reduce the likelihood of HEV outbreaks (Tsega et al., 1991). It is probable that 
outbreaks may be prevented by adequate chlorination of water supplies that are not 
severely contaminated. However, when an HEV epidemic is suspected, all drinking water 
should be boiled or imported from other non-endemic areas, since chlorination alone may 
be unsuccessful in controlling epidemics (www.cdc.gov). To reduce the risk of HEV 
infection, travellers to HEV-endemic areas should be advised to practice prudent 
hygienic practices, including avoidance of untreated drinking water and iced beverages of 
unknown quality. Uncooked shellfish, fruits or vegetables should also be avoided. In 
laboratory settings, the use of iodinated disinfectants or autoclaving is believed to destroy 
HEV (Ticehurst, 1999; Labrique et al., 1999). 
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 1.6.2 Control 
 
Controversy remains as to whether immune globulin prophylaxis is efficacious, even if it 
is prepared from HEV-endemic populations (Labrique et al., 1999). Passive 
immunization was not successful in preventing infection in two nonhuman primate 
studies (one used immune globulin from a human volunteer with historical HEV 
infection, and the other used late convalescent plasma from a previously infected 
cynomolgus monkey (cynos; Tsarev et al., 1994a; Chauhan et al., 1998).  The use of 
immune globulin in an HEV outbreak in India did not reduce disease rates in a controlled 
study (Khuroo and Dar, 1992). Furthermore, treatment of pregnant women with immune 
globulin did not demonstrate a significant reduction in adverse events (Arankalle et al., 
1998). Since there is no specific treatment for hepatitis E infection, patient management 
is primarily supportive. 
 
Further studies reported the use of recombinant HEV proteins as a candidate HEV 
vaccine in cynos (Krawczynski and Bradley, 1989a). A  recombinant protein encoded by 
two-thirds of HEV ORF2 (Burma strain), C51, was used to immunize cynos. When the 
animals were subsequently challenged with intravenous inoculation of the HEV Burma 
strain, a significant improvement of symptoms was observed. In another study, cynos 
immunized with trpE-C2 protein did not develop hepatitis after challenge with wild-type 
HEV from either a Burmese or Mexican stool isolate (Purdy et al., 1993). Studies at the 
National Institute of Health, Bethesda (USA) using an ORF2-derived 55-kD protein from 
HEV (strain SAR-55 from Pakistan) as a vaccine in cynos showed similar results 
demonstrating full protection against challenge with wild-type HEV. Protection against 
genetically distinct strains was provided by this vaccine. Multiple doses of vaccine 
increased the protective effect of the vaccination against an HEV challenge. A 62-kD 
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recombinant protein derived from the putative capsid protein encoded by ORF2 was used 
in studies conducted at the Center for Disease Control, Atlanta (USA). Full protection 
against HEV infection was reported in animals receiving a 62-kD HEV vaccine, as 
opposed to the control animals showing symptoms of HEV disease. Post-exposure 
vaccination has been shown not to be protective against disease (Irshad, 1999).  
 
 1.6.3 Treatment 
 
Presently there is no treatment for HEV infection. The most serious and life-threatening 
complication is the development of fulminant hepatic failure. The therapy of acute liver 
failure has been reviewed (Caraceni and van Thiel, 1995). Medical management in an 
intensive care unit is indicated in the case of progressive deterioration and development 
of fulminant hepatic failure as a result of acute viral hepatitis. A variety of nonspecific 
measures can result in effective symptomatic relief. Bed-rest is indicated for the 
symptomatic patient. Dietary restrictions are unnecessary with the exception that alcohol 
and other potential hepatotoxic drugs should be avoided. Hepatic encephalopathy is a 
hallmark of acute liver failure and therapies are generally directed to a reduction in any 
factor that might exacerbate or predispose to its development. Cerebral oedema is a 
severe complication of stage III/IV hepatic encephalopathy in 50 to 85 % of patients. 
Intracranial pressure monitoring is useful in prompting early intervention for and 
prevention of serious sequelae (e.g brain stem herniation) by treatment with mannitol 
(Caraceni and van Thiel, 1995). Other complications in acute liver failure include 
bacterial and fungal infections and coagulopathy. Prophylactic antibiotic therapy and 
fresh frozen plasma are useful in decreasing the infection rate and complications due to 
bleeding, respectively (Caraceni and van Thiel, 1995). There are no hepato-protective or 
anti-inflammatory agents proven efficacious in acute liver failure. Survival rates may 
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increase to 60 to 80 % with orthotopic liver transplantation (Reyes, 1997). 
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CHAPTER 2: EPIDEMIOLOGY 
 
 
Historically HEV epidemiological study designs involved retrospective investigations of 
sera from reported ET-NANB epidemics. More recently, however, many cross-sectional 
prevalence studies of healthy high and low risk populations, as well as hospital based 
case-control studies of patients admitted with acute hepatitis have been described. 
Laboratory methods used in these studies include exclusion of hepatitis A, B and C, IEM, 
ELISA, western Blot, RT-PCR and sequence analysis (see paragraph 1.3.3). 
 
Outbreaks and high seroprevalence of HEV have been reported from many, mainly 
tropical regions, including India, Pakistan, Bangladesh, Nepal, Myanmar, Borneo, 
Algeria, Somalia, Sudan, Ivory Coast, Mexico, Saudi Arabia, China, Chad, Egypt, 
Ethiopia, Botswana, some former Soviet republics, including Kazakstan, Tajikistan, 
Turkmenistan and Uzbekistan and more recently Kenya, French Territories of Afars and 
Issas (FTAI), Morocco, Nigeria and Namibia (Figure 2.1 and Table 2.1). Although 
hepatitis E is most commonly recognized to occur in large outbreaks, HEV infection also 
accounts for > 50 % of acute sporadic hepatitis in both children and adults in some highly 
endemic areas (www.cdc.gov). In the United States and other non-endemic areas, where 
outbreaks of hepatitis E have not been documented to occur, a low prevalence of anti-
HEV (2 % or less) has been found in healthy populations, indicating that HEV is 
responsible for both sporadic illness and in-apparent infection. Between these two 
extremes are countries, normally neighboring endemic areas, with little or no sporadic 
HEV where studies report considerably more than a 2 % prevalence of HEV antibodies in 
cohorts of healthy individuals. Since none of the individuals had a history of contact with 
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Figure 2.1 Global distribution of hepatitis E virus. Red regions represent areas 
where documented outbreaks of HEV infection have occurred or where >25% of 
sporadic non-A, non-B, non-C hepatitis is attributable to HEV. Adapted from the 
Center for Disease control website (http://www.cdc.gov/ncidod/diseases/hepatitis/
slideset/hep_e/slide_5.htm).   
others who were involved in outbreaks of viral hepatitis or related diseases, it appears 
that they represent cases of sporadic subclinical HEV infection. 
 
2.1 Epidemic outbreaks and prevalence studies in regions in which HEV is endemic 
 
Large epidemics have been reported in Africa, Asia and Eurasia and outbreaks are 
reported on a recurring basis on the Indian subcontinent (Table 2.1). Epidemiological and 
clinical characteristics, which are characteristic of hepatitis E outbreaks in these regions, 
include: 
• Faecal-oral transmission 
• Occurrence of water-borne outbreaks 
• Typical age distribution pattern with predominant involvement of teenagers and 
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Table 2.1 Documented epidemics or sporadic outbreaks of enterically transmitted 
NANB hepatitis 
Table 2.1 continued on next page 
Site Dates Number of 
cases 
Method(s) used Reference 
Asia     
India     
New Delhi 1955-56 29,300 RA, X, EI Labrique et al., 1999 
Ahmedabad 1975-76 2,572 RA, X, EI Labrique et al., 1999 
Kashmir 1978 275 EI Labrique et al., 1999 
Gulmarg (Kashmir) 1978 20,000  Labrique et al., 1999 
Sopore (Kashmir) 1979 6,000  Labrique et al., 1999 
Ambala/Karnal 1980-1981 865 X Labrique et al., 1999 
Azamgarh 1980 152 X Labrique et al., 1999 
Kolhapur (Pune) 1981 1,169 RA, EI Labrique et al., 1999 
Jammu 1981 206 X Labrique et al., 1999 
Harwara (Kashmir) 1981-1982 11,000 X Labrique et al., 1999 
Kupwara (Kashmir) 1981-82 15,000 X Labrique et al., 1999 
Ahmedabad 1982 1,072 RA, EI Labrique et al., 1999 
Ahmedabad 1984 118 RA, EI, IEM Labrique et al., 1999 
Baroda 1984 3,005 RA, EI Labrique et al., 1999 
Surat  1985 1,395 RA, EI Labrique et al., 1999 
Ahmedabad 1986 1,015 RA, EI Labrique et al., 1999 
South Delhi 1987 43 X Labrique et al., 1999 
Karnal, Haryana 1987 1,273 EI Labrique et al., 1999 
Ahmedabad 1987 2,215 RA, EI Labrique et al., 1999 
Jammu 1988 518 RA, X, PCR Labrique et al., 1999 
Khadakwasla 1989 276 RA, EI Labrique et al., 1999 
Akluj 1990 139 RA, EI Labrique et al., 1999 
Beed 1990 >3,000 RA, EI Labrique et al., 1999 
Rewa 1990 517 RA, EI Labrique et al., 1999 
Bijapur 1990 >158 X, IEM Labrique et al., 1999 
Hyderabad 1990 >158 X, IEM Labrique et al., 1999 
Kolhapur 1991 1,442 RA, EI Labrique et al., 1999 
Kanpur 1991 79,091 X, PCR Labrique et al., 1999 
Aligarh 1991 >77 PCR Labrique et al., 1999 
Karad 1993 2,427 RA, EI Labrique et al., 1999 
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Site Dates No. of 
cases 
Method(s) used Reference 
Asia     
Nepal     
Kathmandu 1973-74 10,000 RA Labrique et al., 1999 
Kathmandu 1981-82 4,337 X Labrique et al., 1999 
Kathmandu 1987 370  Bradley, 1992 
Kathmandu 1995 32 EI  
     
Pakistan     
Mardan 1984 >8 RA, X Labrique et al., 1999 
Rawalpindi 1985 >11 RA, X Labrique et al., 1999 
Quetta 1985 >53 RA, X Labrique et al., 1999 
Karachi 1986   Irshad, 1999 
Sargodha 1987 133 IEM, RA, X, EI Labrique et al., 1999 
Abbottabad 1988 190 RA, EI Labrique et al., 1999 
Islamabad 1993-94 3,827 EI Labrique et al., 1999 
     
Bangladesh     
UN Haiti unit 1995 4 EI Labrique et al., 1999 
     
USSR      
Kirgizstan, 
Republic 
1955-1956 10,812  Irshad, 1999 
 1982-1983   Irshad, 1999 
     
Myanmar     
Mandalay 1976-1977 20,000 RA, X Labrique et al., 1999 
Rangoon 1982-83 399 X Irshad, 1999 
Yangon 1989 111 EI Labrique et al., 1999 
     
China     
Xinjiang 1986-88 120,000  Cao et al., 1991 
     
Table 2.1 (continued) 
Table 2.1 continued on next page 
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Site Dates No. of 
cases 
Method(s) used Reference 
Borneo     
Indonesia 1987-1988 2,000  Bradley, 1992;  
Irshad, 1999 
     
Central America     
Costa Rica     
San José 1976 5  Irshad, 1999 
     
Mexico     
Telixtac 1986 129  Bradley, 1992 
Huizililla 1986 94  Irshad, 1999 
     
Middle East     
Saudi Arabia     
Qatar 1981 91  Irshad, 1999 
     
Africa     
Algeria     
Mostaganem 1979-1980 26 PCR, EIA Coursaget et al.,1996; van 
Cuyck-Gandre et al.,1997 
Medea 1980-1981 788  Bellabes et al., 1985; 
Bradley, 1992; Irshad, 1999 
     
Botswana     
Maun 1985 273 X Byskov et al., 1989 
     
Chad     
N’Djamena 1983-1984 38 EIA, PCR Bradley, 1992; van Cuyck-
Gandre et al.,1997 
     
Ethiopia     
Asmera 1988-1989 >750 EI Tsega et al., 1992 
     
Kenya     
refugees 1991 151 EI Mast et al., 1994 
Table 2.1 (continued) 
Table 2.1 continued on next page 
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Site Dates Number of 
cases 
Method(s) used Reference 
Kenya     
 1991 151 EIA Favorov et al., 1994 
     
FTAI     
Djibouti 1992-1993 45  Coursaget et al.,1996 
     
Somalia     
Medea 1980-1981 57 X Belabbes et al., 1985 
Refugee camps 1985-1986 129  Bradley, 1992; Irshad, 
1999 
Tug Wajale 1986 >2,000 IEM CDC, 1987 
Shebli 1988-1989 >145 EI Mushahwar et al., 1993 
     
Sudan     
E. Sudan 1985 2,012 X Bradley, 1992; Irshad, 
1999 
     
Namibia     
Kavango 1983 16 EIA, PCR Isaacson et al 2000; He 
et al., 2000 
     
Ivory Coast     
Tortiya 1983-1984 623 X Sarthou et al., 1986 
     
Morocco     
Casablanca 1994  EI, PCR Benjelloun et al., 1997; 
Meng et al., 1999 
     
Nigeria     
Harcourt 1997-1998 10 PCR Buisson et al. 2000 
     
Egypt     
Cairo 261 58 EI, PCR Tsarev et al., 1999 
Table 2.1 (continued) 
RA, retrospective analysis of sera; EI, enzyme immunoassay; IEM, immune electron microscopy; PCR, polymerase chain 
reaction; X, exclusion of hepatitis A, B, and C viruses. A blank cell indicates that no data were available. For some large 
outbreaks, a smaller sample of cases was serologically examined. 
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young adults (15 to 40 years old) 
• Low secondary attack rate among household contacts 
• Severe fulminant hepatitis with a high case-fatality rate among sick pregnant women 
and  
• The absence of chronic sequelae. 
 
 2.1.1 The Indian Subcontinent 
 
Apart from the New Delhi outbreaks of 1955 and 1987 and the Ahmedabad outbreaks of 
1976, 1982, 1984, 1986 and 1987 (Labrique et al., 1999), epidemic and sporadic non-A, 
non-B (NANB) hepatitis outbreaks have been documented in Kashmir, northern India 
(1978, 1979 and 1981-1982; Khuroo, 1991), Central India (1990: Akluj, Beed, Rewa, 
Bijapur; Arankalle et al., 1994); including Hyderabad (Jameel et al., 1992), Kolhapur in 
the South West in both 1981 and 1991 (Arankalle et al., 1994; Khuroo, 1991) as well as 
the largest South Asian epidemic which occurred in Kanpur, India, South East of New 
Delhi (Ray et al., 1991). 
 
Outbreaks of epidemiologically similar cases of hepatitis E have also been reported in 
other countries of the Indian subcontinent including Myanmar (previously Burma), 
Bangladesh, Nepal and Pakistan (Labrique et al., 1999; Table 2.1).  
 
Between June 1976 and August 1977, more than 20,000 icteric cases occurred in 
Mandalay, Burma, with a case fatality rate of 18 % in pregnant women. An epidemic of 
viral hepatitis involving 10,000 cases in the Kathmandu valley, Nepal, in 1973 was also 
reported to be associated with a high mortality rate in infected pregnant women (Bradley, 
1992). Epidemics have been documented in Pakistan in 1984 (Mardan), 1985 
(Rawalpindi and Quetta; Malik et al., 1988), 1987 (Sargodha; Ticehurst et al., 1992; 
Bryan et al., 1994), 1988 (Abbottabad; Yarbough et al., 1994) and 1993/94 (Islamabad; 
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Rab et al., 1997) and the occurrence of hepatitis E in Pakistan was also recently inferred 
from the observation of cases of disease imported into the United States (de Cock et al., 
1987). 
 
 2.1.2 Documented epidemics in the rest of Asia and Eurasia 
 
Stable foci of HEV disease exist in Central Asia in the former USSR as well as both 
Taiwan and the Chinese mainland (Balayan, 1997) including the Xinjiang Uighur 
Autonomous Region (XUAR; Yin et al., 1993 and 1994), Beijing, Liaoning province, 
Henian province (Wang et al., 1999) and Guangzhou, south of China. 
 
In South-east Asia there are epidemic foci centered in jungle, riverine environments from 
Indonesia (Corwin et al., 1999), Viet Nam (Hau et al., 1999) and Malaysia (Seow et al., 
1999). 
 
 2.1.3 Epidemics in the New World 
 
NANB hepatitis associated with faecally contaminated drinking water has been 
documented in two rural villages located south of Mexico City, Mexico (Bradley, 1992). 
More than 90 cases of presumed hepatitis E were recorded in Huitzililla, Mexico between 
June and October of 1986. Additional cases of NANB hepatitis were seen in Telixtac, 
Mexico shortly thereafter (Table 2.1). Virological and serological studies of stool and 
serum specimens obtained from affected persons, suggested that the aetiological agent 
responsible for disease in North America might be similar to that associated with 
hepatitis E in other regions of the world. This was later confirmed by Huang et al., in 
1992 after cloning and sequencing the Mexican isolate. 
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Figure 2.2. Distribution of HEV epidemics (red) in Africa together with regions of 
high  (blue, defined in the text) or intermediate (yellow) endemicity or alternatively 
non-endemic regions (green). References for this map can been found in the 
relevant tables: Table 2.1, Table 2.2, Table 2.3 and Table 2.4.  
 2.1.4 Documented epidemics in North, East, West and Central Africa 
 
Outbreaks of hepatitis E have also been reported in Africa, including Morocco, Algeria, 
Ivory Coast, Senegal, Nigeria, Egypt, Chad, eastern Sudan, Ethiopia, Somalia, Kenya and  
Angola (Table 2.1 and Figures 2.1 and 2.2). 
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Acute hepatitis E was diagnosed in 77.3 % of patients and 10.4 % healthy contacts after 
an outbreak in the south of Morocco in 1994 (Benjelloun et al., 1997). Controls collected 
from the west of Morocco were also found to be positive for anti-HEV IgG (6.1 %). 
Between October 1980 and January 1981, more than 780 cases of NANB hepatitis were 
documented in Algeria and linked to the use of faecally contaminated drinking water 
(Belabbes et al., 1985). Mostly young adults were affected and 9/9 infected pregnant 
women died as a direct result of NANB hepatitis. A similar outbreak with NANB 
hepatitis cases (N = 623) was observed in Tortiya, Ivory coast, between 1983 and 1984, 
again a high mortality rate among infected pregnant women was noted (Sarthou et al., 
1986).  
 
Large outbreaks of hepatitis E have also been documented in Eritrean and Tigrean 
refugees from Ethiopia residing in refugee camps in eastern Sudan (Bradley, 1992). More 
than 2,000 cases occurred in these refugees between June and October 1985, after the 
onset of heavy rains. Eleven of 63 individuals who died were pregnant women. Between 
1985 and 1986, more than 2,000 cases and 87 deaths due to hepatitis E were noted in 
Ethiopian refugees residing in Tug Wajale and other camps in northwest Somalia 
(Bradley, 1992). The mortality rate among pregnant refugee women in their second and 
third trimester was greater than 17 % and standing faecally contaminated rain water was 
implicated as the vehicle for virus transmission. 
 
Subsequently, an outbreak of acute HEV infection was reported among military 
personnel in northern Ethiopia between October 1988 and March 1989 in some military 
barracks in the Keren district (Tsega et al., 1991). Twenty-eight of the 30 (93 %) 
randomly collected sera from the patients were positive for anti-HEV, indicating that 
HEV infection was the most likely cause of this and other waterborne epidemic outbreaks 
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in a population already immune to HAV infection. There are indications that ET-NANB 
epidemics occur frequently in Ethiopia where crowding and poor hygiene prevail.  
 
Somalia has frequently been the centre of massive humanitarian relief efforts. A major 
part of the relief effort has come in the form of medical aid because of the breakdown of 
medical care and the high rates of mortality due to preventable infectious diseases. One 
such humanitarian relief effort involved military troops from more than 20 countries 
deployed to Somalia on 9 December 1992 by the United Nations in an operation called 
Restore Hope (Burans et al., 1994). In support of this, the United States military 
established a diagnostic laboratory for infectious diseases, the Joint Forward Laboratory, 
in Mogadishu, Somalia. Staff members evaluated 31 Somalis, five displaced Ethiopians 
and three western relief workers who had acute clinical hepatitis. IgM antibody to HEV 
was found in 20 (65 %) of 31 Somalis, two (40 %) of five Ethiopians and two (67 %) of 
three western relief workers. These data indicate that HEV was a common cause of acute 
sporadic hepatitis in Somalia during the initial stages of Operation Restore Hope. The 
outbreak occurred in multiple, separate locations. This finding suggests that HEV is not 
just a cause of epidemic disease but that it is endemic in Somalia and a common cause of 
acute sporadic hepatitis. 
 
HEV infection was confirmed to be the aetiological agent of two further NANB hepatitis 
epidemics, one observed in Algeria (1979-1980) and the other in Djibouti, the capital of a 
small East African country, FTAI in 1992 to 1993 (Coursaget et al., 1996). Among the 
cases involved in the NANB epidemics observed in Algeria and FTAI, HEV infections 
were diagnosed in 81 and 64 % of them respectively.  
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Apart from the outbreaks in Algeria, Sudan, Somalia, Morocco, Ethiopia and FTAI, other 
outbreaks have also been observed in Chad (van Cuyck-Gandre et al., 1996), Kenya 
(Mast et al., 1994), Nigeria (Buisson et al., 2000), the Gambia and Angola, all of which 
have the characteristics of HEV infections. Sporadic cases of HEV have been identified 
as well, in Egypt (Tsarev et al., 1999), Sudan (Hyams et al., 1992), Chad (Coursaget et 
al., 1998), Nigeria (Buisson et al., 2000), Tunisia and Burundi (Coursaget et al., 1996). 
 
It is of note that imported infections observed in French patients or immigrants to France 
have been contracted in Algeria, Benin, Ivory Coast, Morocco and Senegal, confirming 
the results of the detection of HEV infection in African countries (Coursaget et al, 1996). 
 
 2.1.5 Documented outbreaks in southern Africa 
 
The first indication of hepatitis E in southern Africa was a typical waterborne outbreak 
with 273 cases and at least four deaths in 1985 in Maun, northern Botswana (Byskov et 
al., 1989). It was known before the outbreak that most adults were immune to HAV, 
most had markers indicating past infection with HBV and a proportion of people had 
antibodies to hepatitis delta virus (HDV). The epidemic curve suggested that there was a 
major common source of infection, the disease appeared to have affected 1-2 % of the 
population; 90.3 % (214/237) of patients for whom information is available were aged 20 
years or older; the disease was generally mild and affected pregnant women most 
severely. Forty-nine patients were admitted to hospital and at least 4/273 died. The main 
features of the outbreak conformed to public descriptions of waterborne epidemic NANB 
hepatitis and it is postulated that the disease was most severe in patients with acute HBV 
infection and in those with HDV superinfection. Although this is the first description of a 
possible outbreak of waterborne NANB hepatitis in southern Africa, the first confirmed 
38 
outbreak to be molecularly characterized occurred at Rundu in the Kavango region of 
north-east Namibia in 1983 (Isaacson et al., 2000; He et al., 2000). The disease was 
usually mild, except in pregnant women who made up six of the seven fatal infections 
reported in the outbreak. HEV was detected by RT-PCR in faeces from nine of 16 
patients tested and their phylogeny was later established from a consensus sequence of 
296 bp derived from the extreme 3’ region of ORF2. 
 
2.2 Prevalence of HEV antibody in populations in regions of intermediate 
endemicity  
 
Countries bordering endemic regions in which sporadic acute hepatitis is rare or absent 
have often been found to have a fairly high prevalence of HEV antibodies within the 
healthy population. It is not clear whether this is the result of sub-clinical HEV infection 
as the individuals were neither sick nor in contact with apparent viral hepatitis. South 
Africa is an example of one such region (Table 2.2). 
Table 2.2 Prevalence of HEV among populations in regions of high and intermedi-
ate endemicity 
Site Number 
tested 
%  
Seroprevalence 
Population 
tested 
Reference 
Thailand 269 6.5 Hmong people Louisirirotchanakul et al., 
2002 
Hong Kong 355 16.1  Lok et al., 1992 
Turkey 1,350 5.9 NANB Thomas et al., 1993 
Chile 594 7.4 Healthy children, 
prisoners & 
blood donors 
Ibarra et al., 1994 
Brazil 93 11.3 Blood donors Trinta et al., 2001 
Tunisia 72 4 NANB Coursaget et al., 1995 
Venezuela 223 5.4 Rural  
Amerindians 
Pujol et al., 1994 
South Africa 555 1.8 canoeists Grabow et al., 1996 
 227 2.6 Medical students Grabow et al., 1996 
 360 19.1 Rural adults Tucker et al., 1996 
 407 5.8 Urban adults Tucker et al., 1996 
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The first known imported case of hepatitis E into South Africa was a 34-year-old 
pregnant woman who was admitted to the Groote Schuur Hospital in Cape Town in 1992 
shortly after returning from holiday in Bombay, India and this nosocomial outbreak is 
described in paragraph 1.5.3 (Grabow et al., 1996). Hepatitis E was also diagnosed in a 
45-year-old female admitted to the H F Verwoerd Hospital, now called Pretoria 
Academic Hospital, with clinical hepatitis shortly after returning from vacation in India 
(Grabow et al., 1996). 
 
A typical anti-HEV IgG study in South Africa involved healthy, low-risk, medical 
students and high risk Dusi canoeists (Grabow et al., 1994 and 1996). HEV antibodies 
were found in ten of 555 canoeists (1.8 %) with regular exposure to sewage-polluted 
water and six of 227 (2.6 %) medical students with minimal exposure in this 
seroprevalence study. The overall prevalence of 16/782 individuals (2.05 %) suggests 
that HEV may be endemic in South Africa, particularly since four of the persons had 
never been out of the country. At least seven of the remaining positive cases had only 
visited other parts of Africa or Mediterranean countries on rare occasions, suggesting that 
exposure to the virus occurred in South Africa. None of the above individuals had a 
history of contact with others who were involved in outbreaks of viral hepatitis or related 
diseases. It would therefore appear that all of them represent sporadic cases of subclinical 
infection. The higher seroprevalence of anti-HEV among students (2.6 %) as compared 
with canoeists (1.8 %) indicates that regular exposure to sewage-polluted water was not a 
risk factor for HEV infection in the communities concerned. Grabow’s studies classify 
South Africa as a typical non-endemic region. The source of HEV exposure in South 
Africa remains unknown and no symptoms of clinical disease were recalled. The 782 
selected individuals can be considered as fairly representative of middle to high 
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socioeconomic communities in this country. The communities are not considered at high 
risk for a disease which is primarily associated with circumstances of inadequate public 
sanitation and malnourishment.  
 
A study to evaluate the general population of South Africa, and particularly high risk 
communities, was published by Tucker et al in 1996. This study recorded the  
seroprevalence of anti-HEV in 360 rural and 407 urban adult black South Africans living 
in the Western and Eastern Cape provinces and showed a prevalence of 19.1 and 5.8 %, 
respectively, placing South Africa in an intermediate position between the typical 
endemic and non-endemic HEV regions of the world. 
 
The seroprevalence for antibodies to HEV was also determined in a large group of 
Mozambican refugees living in Swaziland, a small landlocked kingdom within South 
Africa (van Rensburg et al., 1995). Serum samples collected from a total of 398 refugees 
located in two camps (Ndzevane and Malindza) showed a total anti-HEV prevalence of 
1.5 %. 
 
Other seroepidemiological surveys of hepatitis E in healthy individuals are shown in 
Table 2.2. In one survey in Hong Kong conducted to validate the recombinant-based 
enzyme immunoassay for the diagnosis of hepatitis E, serum from 394 patients with 
acute viral hepatitis and 355 healthy subjects was tested and 65 (16.5 %) patients with 
hepatitis were found to be positive for IgM anti-HEV and 57 (16.1 %) of the healthy 
subjects were found to be positive for IgG anti-HEV (Lok et al., 1992). In Turkey, the 
seroprevalence and risk factors for infection with HEV were analyzed in five different 
areas where antibodies to HEV were found in 80 (5.9 %) of 1 350 subjects (Thomas et 
al., 1993). The presence of anti-HEV was investigated in blood samples from 166 
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healthy children, 66 male prisoners and 237 blood donors from Chile. Sixty of 166 (36 
%) healthy children were found to be positive for both anti-HEV and anti-HAV. Since 
there were no reports of clinical hepatitis in any of the children the infection must have 
occurred subclinically (Ibarra et al., 1994). 
 
2.3 Incidence of HEV and reports of rare sporadic outbreaks in non-endemic 
regions 
 
Acute sporadic hepatitis E has been reported from every continent: North America (Erker 
et al., 1999; Schlauder et al., 1998), Europe (Schlauder et al., 1999; Balayan, 1993) 
including the United Kingdom (Wang et al., 2001), industrialized regions of Asia 
including Taiwan (Hsieh et al., 1999) and Japan (Takahashi et al., 2002a and 2002b), 
Malaysia (Seow et al., 1999), Australia (Moaven et al., 1993) and Africa (Grabow et al., 
1996). The high rate of prevalence of anti-HEV in healthy subjects is thought to be an 
indication of the existence of considerable subclinical infection (Lin et al., 2000) 
although the constant presence of anti-HEV among normal populations particularly in 
non-endemic regions has yet to be adequately explained (Table 2.3). In one study the 
seroprevalence of antibodies to HEV in the normal blood donor population and two 
aboriginal communities in Malaysia were examined (Seow et al., 1999). IgG anti-HEV 
were detected in 45 (44 %) of 102 samples and 15 (50 %) of 30 samples from the two 
aboriginal communities respectively, compared to only 2 (2 %) of 100 normal blood 
donors and this indicates that the aboriginal communities are at high risk of exposure to 
HEV as compared to the normal (urban) population. 
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No outbreak of clinically overt hepatitis E has ever been documented in the United States 
of America (USA), Canada, Europe, Japan, Australia and New Zealand. In these 
countries, only sporadic cases are occasionally observed among immigrants and 
travellers returning from disease-endemic areas. However, seroprevalence studies of 
different population groups suggest that 0.4-3.2 % of the population have been exposed 
to the virus (Lavanchy et al., 1994; Paul et al., 1994; Zaaijer et al., 1993; Zanetti et al., 
1994). Recent findings in the Netherlands (Zaaijer et al., 1993), Italy (Zanetti et al., 
Table 2.3 Prevalence of HEV among normal/healthy populations in non-endemic 
countries 
Site Number tested % Seropositive References 
Italy 2,233 1.5 Rapicetta et al., 1999 
Haiti 105 3 Gambel et al., 1998  
Belgium 556 2.2 Vandenvelde et al., 1994 
Switzerland 94 3.2 Lavanchy et al., 1994 
Venezuela 204 3.9 Pujol et al., 1994 
Israel 1,139 2.6 Karetnyi et al., 1995 
Netherlands 1,275 1.5 Zaaijer et al., 1993 
UK 1,500 1 Balayan, 1997 
Germany 972 2.1 Balayan, 1997 
France 1,007 0.9 Balayan, 1997 
Russia 168 1.2 Balayan, 1997 
Ukraine 1,721 0.5 Balayan, 1997 
Australia 279 0.4 Balayan, 1997 
USA 386 2.1 Balayan, 1997 
Malaysia 100 2 Seow et al., 1999 
Vietnam 646 9 Hau et al., 1999 
Spain 54 5.5 Jardi et al., 1993 
Taiwan 984 4.4 Lee et al., 1994 
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1994), Greece (Tassopoulos et al., 1994), Taiwan ( Hsieh et al., 1998), Argentina 
(Schlauder et al., 2000), Austria (Worm et al., 2000), USA (Tsang et al., 2000; Schlauder 
et al., 1998) and Japan (Takahashi et al., 2001 and 2002a) suggest that the lack of a 
foreign travel history does not necessarily exclude the diagnosis of hepatitis E infection 
(Table 2.3). Sporadic cases in Italy and Spain have been attributed to the consumption of 
shellfish from sewage-polluted waters (Langer and Frosner, 1996; Table 2.4). 
Table 2.4 Sporadic cases in non-endemic countries 
Site Source of study group Number tested % Seroprevalence 
Netherlands NANBNC hepatitis patients  6 2.1 
Australia (Victoria) Acute with travel history one case 100 
USA Acute with travel history 6 100 
Taiwan NANBNC hepatitis patients  ? 10 
Italy NANBNC hepatitis patients  10 6.5 
Greece NANBNC hepatitis patients  2 100 
Argentina    Acutely infected patients 2 100 
Japan NANBNC hepatitis patients  87 13 
Spain NANBNC hepatitis patients  90 5.6 
Austria NANBNC hepatitis patients  one case 100 
References: Jardi et al., 1993; CDC, 1993; Hau et al., 1999; Hsieh et al., 1998; Mizuo 
et al., 2002; Moaven et al., 1993; Schlauder et al., 2000; Tassopoulos et al., 1994; 
Zaaijer et al., 1993; Zanetti et al., 1994.     
2.4 Molecular Epidemiology of HEV infection 
 
Thus, HEV is not only an important cause of sporadic and epidemic disease in the 
developing world, but the widespread global mobility we enjoy today makes this 
infectious agent a concern for developed nations as well. Travel has increased the 
propensity for the rapid spread of infectious diseases; pathogens can be imported into 
susceptible populations, where they may easily become established and spread (Drabick 
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et al., 1997). Incidents of  hepatitis E in persons from non-endemic countries is usually 
associated with a history of recent travel to an endemic area. As an export disease, HEV 
has been carried by migrant workers to host nations. As a result of the many recent 
export cases, physicians in the US and Europe, as well as in developing countries, are 
now being advised to consider HEV in the differential diagnosis of acute hepatitis 
(Labrique et al., 1999). 
 
The advent of RT-PCR and sequence analysis has enabled characterization of the virus 
and global comparison of the various strains of HEV as well as providing a means of 
nucleic acid testing (NAT) for HEV. However, molecular assays are dependent on the 
presence of nucleic acid, viremia persists for only a few weeks and part of this time is 
prior to the onset of illness or symptoms (section 1.3.1). Thus of necessity, anti-HEV IgG 
assays must still be used to detect past HEV infection in normal healthy individuals 
particularly in residents of non-endemic areas (Table 2.2 and 2.3). 
 
The genomes of several HEV strains from Asia: Myanmar (previously Burma; Tam et 
al., 1991; Aye et al., 1993), Pakistan (Tsarev et al., 1992; van Cuyck-Gandre et al., 
2000), India (Panda et al., 2000; Donati et al., 1997), Nepal (Gouvea et al., 1998), China 
(Aye et al., 1992; Bi et al., 1993; Yin et al., 1994; Wang et al., 2000); US (Schlauder et 
al., 1998; Erker et al., 1999); and Mexico (Huang et al., 1992) have been entirely 
sequenced, and many partial sequences are available.  
 
Phylogenetic clustering of HEV was previously observed to be geographically related. 
HEV sequences from Asia were closely related to, but could be distinguished from, those 
first found in Africa (Chatterjee et al., 1997; van Cuyck-Gandre et al., 1997; Tsarev et 
al., 1999; Meng et al., 1999; He et al., 2000). A single isolate from Mexico remains the 
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most genetically distant isolate (Huang et al., 1992) sequenced to date. Two human HEV 
isolates and a swine HEV isolate from the United States were described recently and they 
differed from the Asia-African group to the same extent as from the Mexican HEV strain 
(Schlauder et al., 1998; Erker et al., 1999). A novel strain of HEV closely related to US 
strains was recently identified from a patient returning from vacation in Thailand 
(Kabrane-Lazizi et al., 2001). 
 
HEV sequences, orginally classified into three major genetic groups, have, with the 
characterization of the unique Chinese isolate, T1, been tentatively classified into four 
genotypes, I to IV (Widdowson et al., 2003; Figure 2.3). Genomic characterization of 
multiple isolates from Burma and from neighbouring locations in Northern Pakistan and 
Southwest China have demonstrated that isolates from close geographic regions tend to 
be more similar than isolates from distant regions (Aye et al., 1993; Yin et al., 1994). 
Genotype I consists of Asian and African isolates (Meng et al., 1999), genotype II 
includes the prototype Mexican isolate (Meng et al., 1999; previously designated as 
genotype III, Tsarev et al., 1999; Buisson et al., 2000; van Cuyck-Gandre et al., 2000), 
the United States isolates comprise genotype III (Schlauder et al., 1998; Erker et al., 
1999; previously designated as genotype II, Tsarev et al., 1999; Buisson et al., 2000; van 
Cuyck-Gandre et al., 2000) and the unique HEV isolate, designated T1, is the prototype 
of genotype IV (Wang et al., 2000). Genotype IV also includes the Taiwanese isolate 
characterized by Meng et al., 2000. 
 
From these data and others, it is evident that HEV infections are frequent in East and 
North African countries, and present as rare outbreaks in western and southern Africa. 
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 2.4.1 HEV genotype I 
 
Many Asian and African isolates comprise genotype I. Two major subtypes of genotype I 
are apparent from phylogenetic analysis, namely Asian subtype 1-1 and African subtype 
1-2. Within the Asian subtype, there are several clades referred to as the Central Asia (1-
1a) and Burma-India (1-1b) clusters. Hepatitis E has been the predominant type of acute 
hepatitis in Nepal both in adults and children, in sporadic and epidemic forms. Six HEV 
isolates obtained during an 8-year period, from 1987 to 1995, in the Kathmandu valley of 
Nepal (Gouvea et al., 1997) showed close genetic relatedness among themselves (> 96.4 
% identity) and with the Burmese (> 95.5 % identity) and Indian (> 95.3 % identity) 
isolates, and less so with the African (> 94.4 % identity) and the Chinese (> 91 % 
identity) isolates over the helicase, polymerase and capsid genes. Nepali isolates form 
part of the Burma-India evolutionary branch of subgroup 1-1 and the oldest isolate, 
TK78/87, is more similar to the Burmese isolates whereas the most recent isolates are 
closer to the Indian ones.  
 
Partial genomic sequences of epidemic-associated Chinese strains of HEV were obtained 
by direct sequencing of PCR-amplified DNA. Comparison with previously published 
HEV sequences showed a clear relatedness of all Chinese strains to each other and to a 
Pakistani strain (Sar-55; Iqbal et al., 1989; Ticehurst et al., 1992; Tsarev et al., 1992). All 
eight Chinese strains examined had very similar sequences (98.5-99.8 % homology) in 
the regions examined and were much closer to the Pakistani strain, Sar-55, (97.9-98.4 % 
homology) than to the Burmese strains (92.5-93.3 % homology; Yin et al., 1993 and 
1994) comprising the Asian sub-genotype (van Cuyck-Gandre et al., 2000). A second 
Pakistan HEV from a 1988 outbreak in Abbottabad (van Cuyck-Gandre et al., 2000) also 
belongs to the Central-Asian cluster of the Asian sub-genotype. 
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The African isolates, Morocco (Meng et al., 1999); Tunisia (Chatterjee et al., 1997); 
Egypt (Tsarev et al., 1999); Namibia (He et al., 2000); Algeria and Chad (van Cuyck-
Gandre et al., 1996 and 1997), most of which have been partially sequenced, are found to 
be closely related to, but distinct from, the Asian isolates in genotype I and they cluster 
into their own sub-genotype away from the Asian sub-genotype (Tsarev et al., 1999; He 
et al., 2000). In one study, HEV genome was detected by RT-PCR in faecal samples of 
two sporadic cases of hepatitis E in Cairo, Egypt. Sequences of the complete ORF2 and 
complete ORF3 were  determined for the two HEV isolates (Tsarev et al., 1999). Four 
regions of the HEV genome were used for phylogenetic analysis. In all four regions, 
African strains were always clustered together, thus further confirming the geographic 
origin of HEV strain divergence. 
 
 2.4.2 HEV genotype II 
 
In all parts of the genome, the Mexican strain was the most different of the sequences 
studied (Purcell, 1996). The 5' non-coding (NC) region of most strains was 26 to 27 
nucleotides in length, but the 5' NC region of the Mexican strain (originally reported to 
be three nucleotides in length; Huang et al., 1992) is now reported to be 24 nucleotides 
long (Zhang et al., 2001). In the ORF1 region, the Mexican strain was over 25 % 
different from the Asian strains at the nucleotide level, whereas the Asian strains differed 
from each other by less than 10 %. The degree of genetic heterogeneity of the Asian 
strains in ORF2 was similar to that in ORF1 but they differed from the Mexican strain by 
approximately 20 %. ORF3 was the most highly conserved of the ORFs (with the 
exception of the 3' end), varying by less than 2 % among the Asian strains and by 
approximately 10 % in the Mexican strain. Therefore, due to its diversity from the Asian 
isolates, the Mexican strain is the prototype strain of genotype II (Meng et al., 1999) 
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previously designated as genotype III (Tsarev et al., 1999; van Cuyck-Gandre et al., 
2000).  
 
Recently discovered Nigerian isolates cluster together with the Mexican isolate in 
genotype II (Buisson et al., 2000). Sporadic cases of acute hepatitis E among 10 native 
Nigerian adults were reported in Port-Harcourt, Nigeria. HEV was detected in serum and/
or faecal samples of seven patients. Restriction analysis used to distinguish genotypes I 
and II showed that all Nigerian strains have a pattern similar to the Mexican strain but 
displayed a BsmI restriction site at nucleotide 213 as do most African HEV strains 
sequenced so far. Sequence analysis performed from PCR products displayed strong 
homogeneity between the HEV isolates, determining a regional cluster. Phylogenetic 
analysis of nucleotide sequences revealed that these strains were more related to the 
Mexican prototype in genotype II (87 % homology in ORF1, 80 % homology in ORF2) 
than to either the African strain genotype I (74 % homology in ORF1, 77 % homology in 
ORF2) or the USA strain genotype III (75 % homology in ORF1, 77 % homology in 
ORF2). Genetic divergence up to 15 % in ORF2 with the Mexican genotype clearly 
defined a new sub-genotype within genotype II. The Nigerian strains were more 
homologous to genotype II strains (96 %), at the amino acid level, than with genotype I 
strains (92 %). This study determined the co-existence of genotypes I and II in Africa. 
 
 2.4.3 HEV genotype III 
 
Isolates clustering together and away from the Asian, African and Mexican isolates have 
been identified in patients with acute hepatitis in the US and Europe. The latter include 
isolates from Austria (Worm et al., 2000), Italy (Zanetti et al., 1999), Argentina 
(Schlauder et al., 2000), Greece (Schlauder, et al., 1999), Spain (Pina et al., 2000), 
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United Kingdom (Wang et al., 2001), and the Netherlands (Widdowson et al., 2003). 
These US and European isolates comprise genotype III (Mizuo et al., 2002; previously 
designated genotype II).  
 
A variant of HEV, designated HEV US-1, was identified in a hepatitis patient in the US; 
the patient had no history of travel to areas where HEV is endemic (Schlauder et al., 
1998). The HEV US-1 strain is significantly divergent from other human HEV isolates 
with nucleotide identities ranging from 76.8 to 77.5 %. Phylogenetic analysis indicate 
that HEV US-1 and a recently discovered HEV variant from swine (Meng et al., 1997), 
may represent separate isolates of a new strain of HEV, significantly divergent from the 
Mexican and Burmese strains, (Schlauder et al., 1998). Later, the near full-length 
sequences of HEV-US1 and a second US isolate (HEV-US2) were reported (Erker et al., 
1999). HEV-US2 was identified in a US patient suffering from acute viral hepatitis. 
These sequences verify the presence of a new HEV strain in North America and provide 
information as to the degree of variability between variants. The HEV-US nucleotide 
sequences are 92 % identical to each other and only 74 % identical to the Burmese and 
Mexican strains. Amino acid and phylogenetic analysis also demonstrate that the US 
isolates are genetically distinct, clustering away from the Burmese and the Mexican 
isolates. 
 
 2.4.4 HEV genotype IV 
 
Extensive diversity has been noted among HEV isolates from patients with acute 
hepatitis in China (Wang et al., 1999), Taiwan (Wang et al. 2000) and Japan (Takahashi 
et al., 2002b), which are distinct from the original Chinese isolates and comprise 
genotype IV (Mizuo et al., 2002). This suggests that HEV of two distinct genotypes 
51 
circulate in China.  
 
2.5 Specific objectives of this study 
 
Serological and molecular tests for HEV were developed only recently and the first 
molecular characterization of the virus in southern Africa was only published in the year 
2000 (He et al., 2000). Prevalence studies based on serological assessment from different 
populations, have suggested activity by this agent in South Africa (Grabow et al., 1996; 
Tucker et al., 1996) but the virus has never been detected in material from patients with 
clinical episodes of hepatitis. At the National Institute for Virology (NIV), now called the 
National Institute for Communicable Diseases (NICD), where the study was conducted, 
all but one of the hepatitis E cases that have been diagnosed in the routine diagnostic 
laboratories were in-patients returning from the Indian subcontinent and this also has 
been the experience of other academic laboratories (Grabow et al., 1994).  
 
Although several HEV strains from different geographical areas have been sequenced 
(Aye et al., 1992, 1993; Huang et al., 1992; Tsarev et al., 1992; Bi et al., 1993; Yin et 
al., 1994; Panda et al., 1995; Chatterjee et al., 1997; Donatti et al., 1997; Gouvea et al., 
1998; van Cuyck-Gandre et al., 1997), data are limited from southern Africa. Recent 
reports (Buisson et al, 2000 and He et al., 2000) confirmed that HEV is present in 
southern Africa and characterized the strain of the viruses that resulted in the outbreaks 
which occurred in Nigeria (1997/8) and in Namibia (1983) respectively. The authors 
compare sequence data from portions of ORF1 and ORF2 of the HEV genome from 
patient specimens obtained during the outbreaks.  
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The objectives of this study are thus: 
 
• To establish an HEV PCR for molecular diagnosis of HEV and to use this PCR to 
detect HEV nucleic acid in specimens collected from an acute viral hepatitis outbreak 
in Rundu, Namibia, in 1995 and from a previous outbreak in Maun, Botswana, in 
1983. 
 
• To characterize, using partial sequence analysis, the HEV strain involved in the 
outbreaks and to compare the sequenced strains with other HEV strains circulating in 
sub-Saharan Africa. 
 
• To relate the sequence information to available data from other parts of the world.  
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CHAPTER 3: MATERIALS AND METHODS 
 
 
3.1 Introduction 
 
A non-A non-B hepatitis outbreak involving more than 600 people occurred in 1995/6 in 
the Kavango region of northern Namibia, centered on the town of Rundu (Surveillance 
Bulletin, 1996). Patients presented with symptoms of viral hepatitis (jaundice, fever, 
vomiting, dark urine, diarrhoea, hepatomegaly, haemorrhagic signs and hypochondrial 
pain) and there were at least three fulminant cases, one of whom was a pregnant woman. 
Blood specimens were obtained from 564 patients who were aged from 5 days to 80 
years (median, 25 years) and only 536 are on record with full details. Patients’ sera were 
tested for HEV IgG using the Abbott HEV enzyme immunoassay (EIA) Kit (Abbott 
GmbH Diagnostika, Wiesbaden-Delkenheim, Germany) after onset of illness. Samples 
were considered anti-HEV reactive when the ratio of absorbance to cut-off (OD/CO) was 
greater than 1. Of the 536 patients tested for HEV IgG, 351 tested positive, 151 cases 
tested negative and the rest of the patients were not tested for HEV IgG. The patients 
presented with a total bilirubin range of 17-724 µmol/l, ALT range of 26-6,780 IU/L and 
an aspartate transaminase activity (AST) range of 25-10,540 IU/L. Based on the normal 
reference ranges for the chemistries, which are as follows: ALT in males ranges from 1-
42 IU/L, in females it is 1-32 IU/L; AST in males ranges from 1-37 IU/L, in females it is 
1-31 IU/L; total bilirubin during 0-14 days ranges from 0-20 umol/L and over 14 days it 
ranges from 0-7 umol/L; it was observed that only three of 536 patients on record, two 
females and one male, had chemistries within the normal ranges. One example of a 
normal was a 33-year-old male who had the following chemistries: total bilirubin-28 
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umol/L, AST-25 IU/L and ALT-27IU/L, on his seventh day of illness.          
 
The source of the outbreak is suspected to be the water supply which was compromised 
by the drought and disturbances in reticulation following work on the pipes 
approximately six months earlier. HEV antibodies were detected in approximately 75 % 
of sera specimens from icteric patients with a prevalence of 13 % in patients aged < 10 
years and 81 % in those aged > 50 years. The highest antibody prevalence (81 %) was 
observed in the > 50 years age group with about 60-70 % prevalence seen in the other 
age groups, that is, 10-19, 20-29, 30-39 and 40-49 age groups (Figure 3.1).   
 
Antibodies were not detected in any of the children under the age of five years and 
therefore a diagnosis of HEV could not be made conclusively. IgG avidity tests 
performed on a portion of specimens from icteric patients demonstrated low avidity 
indices with some indices < 10 %. Approval to undertake the study was obtained from 
the Ministry of Health and Social Services of the Republic of Namibia and consent was 
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Figure 3.1 HEV seroprevalence obtained from blood samples from 564 patients suspected of 
HEV infection. The highest antibody prevalence (81 %) was observed in the > 50 years age 
group and a low prevalence of 13 % was observed in patients aged < 10 years and 60-70 % 
prevalence in the other age groups, that is, 10-19, 20-29, 30-39 and 40-49 age groups (male 
to female ratio 1.4:1).      
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obtained from the patients in order to use their specimens for HEV studies (Appendix C). 
 
Another outbreak of suspected water-borne epidemic non-A non-B hepatitis with 273 
cases occurred from June to December 1985 in northern Botswana (Byskov et al., 1989), 
as mentioned in section 2.1.5. The serum samples were separated into three groups: acute 
phase taken 0-2 weeks after onset of jaundice, early convalescence taken at 3-6 weeks, 
and late convalescence taken about nine months after the clinical episode. Residual 
samples of seven sera from the first group, 42 from the second and 28 from the third, 
(total 77), which had been stored at –70 ºC were sent to NICD for HEV antibody tests 
using the Abbott EIA kits (Swanepoel et al., 1995). Anti-HEV IgG antibody was 
detected in 7/7 (100 %) acute, 36/42 (85.7 %) early convalescent, and 19/28 (67.9 %) late 
convalescent phase sera. Avidity index of the antibody, an index of recent primary 
exposure, was significantly greater in specimens taken nine months after the onset of 
illness than in sera taken during the first 30 days of infection. 
 
Clinical specimens, including human stool and serum samples, were obtained from the 
two outbreaks mentioned above in order to characterize the virus that caused the 
outbreaks. The hypothesis is that hepatitis E was the causative agent responsible for the 
two outbreaks.  
 
Two independent regions of the HEV genome, ORF1 and ORF2 were targeted for RT-
nested-PCR amplification, in particular the polymerase (RdRp) region in ORF1 and the 
ORF2 region towards the carboxy terminal end (3’-end) of the genome. The ORF1 
region was targeted because a plasmid with an HEV ORF1 insert was available as a 
positive control for PCR amplification. The ORF2 region was targeted because it is a 
highly immunogenic epitope (Reyes et al., 1993) and most of the published HEV 
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sequences from Africa are from this region and this would allow for a meaningful 
comparative sequence analysis.  
 
Some of the clinical specimens that were used in this study had been stored for more than 
15 years. The virus is, reportedly, difficult to isolate (Ray et al., 1991; Turkoglu et al., 
1996) and this Chapter provides a detailed account of the procedures used to optimize 
PCR conditions for effective amplification of both the ORF1 and ORF2 regions of the 
HEV genome. The aim was to generate a sensitive and reproducible HEV RT-PCR and 
to use the fragments generated to characterize the HEV strain responsible for the two 
outbreaks. 
 
3.2 Patients and clinical material 
 
Clinical material, including human stool and serum samples obtained from 536 patients 
from a documented outbreak of hepatitis E in Rundu, Namibia in 1995 and serum 
specimens obtained from 77 patients from Maun, Botswana in 1983, were stored at -70 
ºC and were available for this study. From the 536 specimens from Namibia, 183 
specimens (88 stool and 95 serum specimens) were chosen randomly and only 16 from a 
total of 77 serum specimens from Botswana were used in this study. The patients from 
both outbreaks (Namibia and Botswana) suffered from mild disease and presented with 
jaundice,  hypochondrial pain, dark urine, fever, arthralgia, mild haemorrhagic signs and 
fatigue (Surveillance Bulletin, 1996; Swanepoel et al., 1996). The Namibian patients’ age 
ranged from 5 days to 80 years (median, 25 years), (Surveillance Bulletin, 1996). Out of 
237 patients from the Botswana outbreak, 214 (90.3 %) of all patients were aged 20 years 
or older (Swanepoel et al., 1996).     
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A plasmid DNA was used initially as a positive control in this study and was obtained 
from Dr T Tucker (then at the University of Cape Town) with permission from Dr S A 
Tsarev (then at the Walter Reed Army Institute of Research). The plasmid consists of an 
HEV insert of 2,002 bp cloned into the circular 3 kb pCR1000 DNA vector which was 
constructed from an E. coli phage and contains a kanamycin resistant site 
(www.invitrogen.com). The cloning site disrupts the β-galactosidase marker gene and 
recombinants (colourless plaques) were differentiated by the plaque assay system. The 
inserted DNA fragment was from the Pakistani Sar55 strain and included most of the 
helicase region (699  bp) and the polymerase/replicase region (1303 bp), both in ORF1 
(Yin et al., 1994). 
 
3.3 Plasmid DNA preparation 
 
 3.3.1 Transformation of competent cells  
 
Fifty microliters of JM109 bacterial high efficiency competent cells were added together 
with 1.5 µl of plasmid in a 1.5 ml microcentrifuge tube, gently mixed and left on ice for 
20 minutes. The mixture was heat shocked for 45 seconds in a water bath at 42 ºC, 
followed by another 2 minutes on ice. SOC medium (Appendix A1.1) was added to the 
mixture and incubated in a 37 ºC G24 shaking incubator (250 rpm; New Brunswick 
Scientific Co. Inc. Edison, N.J, USA) for 1.5 hours. 5-Bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal)/isopropyl-β-D-thiogalactopyranoside (IPTG) Luria broth (LB) agar 
plates were prepared by spreading 40 µl 50 mg/ml IPTG and 30 µl 100 mM X-Gal onto 
petri dishes with LB agar (Appendix A1.2) containing 10 mg/ml kanamycin antibiotic. 
Fifty microliters of the transformed mixture was spread onto X-Gal/IPTG LB agar plates 
and incubated overnight at 37 ºC. E. coli cells infected with the vector will, in the 
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presence of the lac operon inducer IPTG, produce a functional ß-galactosidase enzyme 
which hydrolyses the substrate X-gal to give a blue dye. Appropriate insertion of foreign 
DNA interferes with the production of the enzyme thus recombinant vectors give 
colourless plaques on an E. coli lawn and can be picked out and grown. 
 
One millilitre of LB growth medium (Appendix A1.3) containing 5.0 µl kanamycin (50 µ
g/ml) was inoculated with two colourless plaques and incubated at 37 ºC in a G24 
shaking incubator (250 rpm) for 2 hours, followed by addition of 3 ml LB growth 
medium and incubated for 16 hours (overnight) in a 37 ºC G24 shaking incubator (250 
rpm) and used to make glycerol stocks. 
 
 3.3.2 Plasmid DNA stock preparation 
 
Glycerol stocks of the plasmid DNA were made by adding 150 µl of glycerol to 850 µl of 
the bacterial culture incubated for 16 hours. These were mixed, quick cooled with liquid 
nitrogen and stored at -70 °C. 
 
 3.3.3 Plasmid DNA extraction and purification 
 
Extraction and purification of plasmid DNA was performed by using four different 
commercial kits in order to obtain optimal yields and quality of plasmid DNA. The 
methods were used according to the manufacturer’s protocols as described for each 
briefly below. 
  
● The Nucleon plasmid minipreps kit (Amersham International plc, Buckinghamshire, 
England) protocol required cells from 3 ml of bacterial culture harvested after 16 hours 
and centrifuged in an Eppendorf 5415C centrifuge (Eppendorf-Netheler-Hinz GmbH, 
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Hamburg, Germany) at maximum speed (14 000 rpm). The supernatant was discarded 
and the cell pellet resuspended in solution 1. Solution 2 was added to the re-suspended 
pellet for alkaline cell lysis then solution 3 was added for precipitation of cellular debris. 
The neutralized lysate was centrifuged and the supernatant mixed with DNA binding 
resin and centrifuged again. The pellet was then washed twice with the 1 X wash buffer. 
The pellet was left in an open tube for 5 minutes at 60 °C to remove all traces of ethanol 
from the wash buffer. The pellet was resuspended in the elution buffer and centrifuged to 
separate the eluate containing the adsorbed plasmid DNA from the supernatant. 
 
● The Wizard (TM) Plus Minipreps DNA Purification Systems kit (Promega 
Corporation, Madison, USA) protocol also required a cell pellet from 3.0 ml of bacterial 
culture obtained as above and resuspended and lysed using the cell resuspension and cell 
lysis solutions respectively. The cells were neutralized and mixed with the resin 
suspension. The mixture was applied to a minicolumn followed by wash solution. The 
minicolumn was attached to a 1.5 ml microcentrifuge tube and centrifuged to dry the 
resin. The minicolumn was then attached to a new microcentrifuge tube and 50 µl of 
distilled water was added to the column and centrifuged to elute the DNA.  
 
● The QIAGEN plasmid purification kit (QIAGEN, GmbH, Germany) used cell stocks 
which were cultured differently from the two methods above. One hundred millilitres of 
LB containing 500 µl of 50 µg/ml kanamycin antibiotic was inoculated with a loop which 
had been dipped in the glycerol stock and incubated in a 37 °C G24 shaking incubator 
(300 rpm) for 16 hours. The bacterial culture was then centrifuged and the pellet 
resuspended in buffer P1 containing RNase A. The lysis reaction was initiated by adding 
buffer P2 followed by the addition of buffer P3 for precipitation. The reaction mixture 
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was then incubated and centrifuged at 20,000 g for 30 minutes at 4 °C. The supernatant 
was re-centrifuged for 15 minutes, applied to the QIAGEN-tip containing the resin and 
allowed to enter the resin by gravity flow. The QIAGEN-tip was then washed with buffer 
QC and the DNA eluted with buffer QF. The eluted DNA was precipitated by adding 
isopropanol, and then washed with 70 % ethanol and centrifuged. The pellet was air-
dried and the DNA re-dissolved in distilled water. 
 
● The High Pure Plasmid Isolation miniprep kit (Roche Diagnostics Corporation, 
Mannheim, Germany) protocol uses a cell pellet from 4 ml of bacterial culture 
resuspended in suspension buffer containing RNAse followed by addition of lysis buffer. 
The mixture was incubated at room temperature for 5 minutes when a chilled binding 
buffer was added and the mixture incubated on ice for another 5 minutes and centrifuged. 
The pellet was discarded and the supernatant centrifuged in a filter tube and washed 
twice with buffer I and II respectively. The pellet was resuspended in the elution buffer 
and centrifuged to elute a purified plasmid DNA. 
 
 3.3.4 Agarose gel electrophoresis 
 
The eluted plasmid DNA (5 µl) was mixed with 5 µl bromophenolblue/xylenexyanol 
loading dye and analysed by electrophoresis at 100 volts (V) for an hour on a 1 % 
agarose gel (Appendix A2.1 and A2.2) containing 0.5 mg/ml ethidium bromide (EthBr) 
in tris borate/EDTA (TBE) buffer. Five microlitres (0.25 µg) of 1:5 DNA molecular 
weight marker IV was used to assess the size of the plasmid DNA which was expected to 
be approximately 4,980 bases. The DNA was detected by ultraviolet illumination and 
pictorial records were kept using the GelDoc system (UVP, Upland, California, USA). 
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 3.3.5 Purification of plasmid DNA 
 
Plasmid DNA was ethanol precipitated and the concentration of monovalent cations 
adjusted by dilution with 0.5 M sodium acetate (pH 5.0, Sambrook et al., 1989) to 
remove impurities. One hundred and thirty microlitres of DNA was mixed with 2 
volumes of ice-cold ethanol and placed at -70 °C for 30 minutes. The mixture was then 
centrifuged at 12,000 g for 10 minutes and the supernatant discarded. Five hundred 
microlitres of 70 % ethanol was added to wash the cell pellet which was then centrifuged 
again at 12,000 g for 2 minutes and the supernatant discarded. The tube containing the 
cell pellet was then left open at room temperature, for evaporation of ethanol, and the cell 
pellet resuspended in 50 µl distilled water. 
 
3.4 Verification of the Plasmid 
 
 3.4.1 Restriction enzyme digestion and verification of the Plasmid 
 
Ten microlitres of vector plus insert was digested separately with 10 units of one, or 
more, of the following restriction endonucleases (REs; Boehringer Mannheim), Hind III, 
Sma I and Sac I, using the buffers supplied and the conditions recommended by the 
manufacturers in a final reaction volume of 15 µl. After digestion, the entire reaction 
volume was mixed with gel-loading dye and analyzed by electrophoresis as outlined in 
section 3.3.4. Hind III RE has only one cutting site in the plasmid vector (1,163 bp) and 
none in the HEV insert. Hind III digestion was also performed with a control plasmid, the 
pMosblue vector (2,887 bp) containing a Kaposi sarcoma virus insert (804 bp; 
Alagiozoglou et al., 2000). Hind III has two cutting sites for the control plasmid, one in 
the insert and one in the vector. Sac I RE cuts the plasmid vector once (1,143 bp) and the 
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Table 3.1 Primers used for PCR amplification 
ORF                      Primer                         Location                      Sequence  
  
ORF1a                External sense                 3853-3877 ACA TTT GAA TTA ACA GAC ATT 
GTG C 
External antisense            4926-4903 ACA CAT CTG AGC TAC ATT CGT 
GAG 
Internal sense                   4120-4140 GAC GTG TCC AGG ATC ACC TTC 
Internal antisense             4678-4654 ACT CAC TGC AAA GCA CTA TCG 
AAT C 
ORF2b               External sense                  925-947 CGC AAC CTC ACC CCT GGT AAC 
AC 
External antisense            2012-1991 CAG AAA GAA GGA GGG CAC 
AAG C 
Internal sense                   1256-1277 CTC AGC AGG ATA AGG GTA TTG 
C 
Internal antisense             1983-1963 CTA TAA CTC CCG AGT TTT ACC 
 
a Nucleotide locations of primers are numbered from the start of ORF1 with respect to the sequence isolated from the 
Xinjiang epidemic (GenBank Accession no.: NC_001434) 
b Primer sequences are numbered from the start of ORF2 with respect to the sequence isolated from the Xinjiang 
epidemic (GenBank Accession no.: NC_001434) 
insert twice (3,497 and 4,096 bp). Sma I RE cut once in the plasmid vector (1,395 bp) 
and once in the insert (2,987 bp).   
 
 3.4.2 Sequencing of cloned plasmid DNA 
 
Plasmid DNA was sequenced using the Thermosequenase cycle sequencing kit 
(Amersham International plc, Buckinghamshire, England) which relies on amplification 
of signal intensity by asymmetric PCR. The plasmid was diluted to 0.15 µg in 16 µl 
distilled water to which 2 µl of 2 pmol/µl primers was added. The primers used were 
universal fluorescent primers (M13 reverse primer and M13-20 forward primer). Four, 
0.5 ml microcentrifuge PCR tubes labeled A, C, T and G, (four for each plasmid run) 
were filled with 2 µl of the appropriate A, C, T or G dideoxy termination nucleotide. Six 
microlitres of template/primer mix was added to the four tubes containing the dideoxy 
termination nucleotides and then immediately placed on the GeneAmp PCR System 2400 
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thermal cycler (The Perkin Elmer Corporation, Norwalk, USA) with the following 
cycling conditions: 96 °C for 5 minutes, 30 cycles of denaturation at 96 °C for 30 
seconds and priming and amplification at 60 °C for 30 seconds followed by one cycle of 
denaturation for 30 seconds and 5 minutes of amplification. The reaction was kept at 4 °
C until 4 µl of stop solution was added. Samples were denatured at 90 °C for 3 minutes 
before 4.0 µl was loaded onto a single well of a 5 % Long Ranger gel (Appendix A6) of 
the ALFexpressTM DNA Sequencer (Amersham Pharmacia Biotech Ltd., 
Buckinghamshire, England). 
 
3.5 PCR optimization using plasmid DNA  
 
External sense (nt 3853-3877) and antisense (nt 4926-4903) ORF1 primers (Table 3.1) 
were used for PCR amplification of a 1,074 bp target of the polymerase region in ORF1 
of the HEV genome. The activity of two enzymes, Taq DNA polymerase (Roche 
Diagnostics Corporation, Mannheim, Germany) and Supertherm DNA polymerase (JMR 
Holdings, UK) were compared in parallel experiments with annealing temperature 
optimization. The PCR reaction mixture contained a final concentration of the following 
reagents: 400 nM of both sense and anti-sense primer, 0.125 µl (0.625 U) of the DNA 
polymerase (5.0 U/µl) being evaluated, 5 µl of 10X PCR reaction buffer (Roche 
Diagnostics Corporation, Mannheim, Germany) consisting of 1.5 mM MgCl2, 200 µΜ of 
each deoxynucleoside triphosphate [(dNTPs) – 1 mM diluted 1:5 for each stock 
concentration – deoxy-adenosine triphosphate (dATP), deoxy-guanosine triphosphate 
(dGTP), deoxy-cytidine triphosphate (dCTP) and deoxy-thymidine triphosphate (dTTP)], 
and 2.0 µl of pooled plasmid DNA (maximum 0.6 µg/µl) in a final volume of 50 µl made 
up with distilled water. For annealing temperature optimization the Robocycler gradient 
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40 machine (Stratagene, California, USA) was used with the following thermal cycling 
conditions: 35 cycles of a 95 °C denaturing step for 30 seconds, annealing at 42 to 56 °C 
for 60 seconds (42, 44, 46, 48, 50, 52, 54, 56 ºC - temperature gradient of 2 °C), and 
amplification at 72 °C for 90 seconds. Five microlitres of the PCR products were 
analyzed on a 1 % agarose gel by electrophoresis as described in section 3.3.4. 
 
3.6 Nucleic acid extraction from clinical specimens 
 
 3.6.1 Clarification of stool specimens 
  
The stool specimens were clarified as follows: using a 1.0 ml syringe, 500 µl of 
chloroform was added to a McCartney bottle containing 10 ml of 0.5 % gelatin buffered 
saline (GBS, Appendix A3) with glass beads. A 20 % suspension was made by adding 
2.0 g of stool using an applicator stick. The suspension was shaken vigorously for 20 
minutes and 1.0 ml of sample was added to a 1.5 ml microtube (Sarstedt AG & Co., 
Germany) and centrifuged at 23,000 rpm for one hour at 4 °C using the Jouan MR22i 
centrifuge (The Scientific Group, PTY/Ltd, Johannesburg, S.A). The supernatant was 
discarded and the pellet resuspended in 140 µl phosphate buffered saline (PBS, Appendix 
A4) for RNA extraction. 
 
 3.6.2 Viral RNA extraction 
 
RNA extraction from both stool and sera specimens was performed using either the High 
Pure Viral RNA Kit (Roche Diagnostics Corporation, Mannheim, Germany) or the 
QIAamp® Viral RNA isolation kit (QIAGEN, GmbH, Germany) as recommended by the 
manufacturers. Using the High Pure Viral RNA Kit, 400 µl of binding/lysis buffer was 
added to 200 µl of sample (either clarified stool or serum) and mixed well. The sample 
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was then transferred into a high pure filter column which was placed in a collection tube 
and centrifuged at 10,000 rpm for 15 seconds. The column was then placed into a new 
collection tube and washed twice with 450 µl of wash buffer. This ensured that the bound 
nucleic acids are purified from salts, proteins and other impurities. Finally viral RNA was 
eluted in 50 µl of elution buffer. 
 
Alternatively RNA was extracted using the QIAamp® Viral RNA isolation kit 
(QIAGEN, GmbH, Germany) according to the manufacturer’s instructions: Five hundred 
and sixty microlitres of lysis buffer was added to 140 µl of the sample and incubated at 
room temperature for 10 minutes. This ensured isolation of intact viral RNA as well as 
the inactivation of RNases. After adding an equal volume of 100 % ethanol, the mixture 
was loaded onto the QIAamp spin column. Salt and pH conditions ensure that RNA binds 
to the silica-gel column. Proteins and other contaminants were washed through the 
column using two different wash buffers. Finally, the RNA was eluted in a RNase-free 
buffer. 
 
3.7 Amplification of clinical specimens 
 
Stool and sera specimens obtained from the 1995 Namibia outbreak were used for a 
nested RT-PCR using the same external and internal primers (Table 3.1) and conditions 
(section 3.5) optimized with the plasmid to amplify a first round fragment of 1,074 bp 
and a second round fragment of 559 bp within the HEV polymerase region of ORF1. 
 
A second region of the HEV genome, located towards the carboxy terminal end (3'-end) 
of ORF2, was targeted to amplify a first round fragment of 1,088 bp and a second round 
fragment 728 bp. Primers for both regions were designed using the Primer Detective and 
DNASIS software (version 7.8). 
66 
 3.7.1 Titration of magnesium ion concentration  
 
The PCR conditions for plasmid DNA described in section 3.5 were optimized for the  
ideal MgCl2 concentration to amplify the ORF1 region from clinical specimens using the 
Supertherm DNA polymerase (JMR Holdings, UK). The following six reaction buffers 
were evaluated: 10X Supertherm PCR reaction buffer (JMR Holdings, UK) consisting of 
15 mM MgCl2, 10X Roche PCR reaction buffer (Roche Diagnostics Corporation, 
Mannheim, Germany) also consisting of 15 mM MgCl2 and four 10X in-house buffers 
containing 10, 15, 20 and 25 mM MgCl2 respectively (Appendix A5). The Biometra 
thermal cycler (Biomedizinische Analytik, GmbH, Göttingen, Germany) was used with 
the following cycling conditions: First round RT-PCR - 42 °C for one hour (reverse 
transcription [RT] step), followed by 35 cycles of 95 °C for 30 seconds, 50 °C for 1 
minute and 72 °C for 90 seconds followed by a last elongation step at 72 °C  for 7 
minutes. The reaction mixture was used as described in section 3.5 and the final reaction 
conditions were as mentioned below (section 3.7.2). Nested PCR (100 µl) was performed 
with 5 µl of first round PCR product for each of the six reaction buffers evaluated. The 
nested PCR reaction mixture was the same as the first round PCR reaction mixture 
(section 3.5) but with the ORF1 inner sense and antisense primers (Table 3.1) and the 
same cycling conditions used for the first round PCR with the exception of the RT step. 
Ten microlitres of the PCR product was analyzed on a 1 % agarose gel by electrophoresis 
as described in section 3.3.4. 
 
The RT-PCR conditions described for ORF1 above were optimized for amplifying the 
3’-end of ORF2. The Supertherm DNA polymerase was used together with its 10X 
corresponding PCR reaction buffer (JMR Holdings, UK). Titration of magnesium ion 
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concentration was only optimized with the Supertherm PCR reaction buffer and was used 
at two different initial concentrations of MgCl2, that is, 10 mM and 15 mM MgCl2, 
respectively. The annealing temperature was also optimized for ORF2 using the 
Robocycler gradient 40 machine (Stratagene, California, USA) with the following 
thermal cycling conditions: 42 °C for 60 minutes, 35 cycles of a 94 °C denaturing step 
for 60 seconds, annealing at 42 to 56 °C for 60 seconds (42, 44, 46, 48, 50, 52, 54, 56 ºC 
- temperature gradient of 2 °C), and amplification at 72 °C for 80 seconds.  The final 
concentration of the PCR reaction mixture was the same as described for ORF1 (section 
3.5) but with the use of ORF2 external sense and antisense primers (Table 3.1). Second 
round (nested) PCR (100 µl) was performed with 10 µl of first round PCR product and 
10 µl of the nested PCR products were analyzed on a 1 % agarose gel by electrophoresis 
(section 3.3.4).       
 
 3.7.2 Final RT-PCR 
 
Final RT-PCR concentrations for amplifying the polymerase region in ORF1 were as 
follows: First round RT-PCR - 400 nM of both ORF1 external sense and antisense 
primers (Table 3.1), 200 µM each dNTPs, 0.625 U of Supertherm DNA polymerase 
(JMR Holdings, UK), 1.0 mM MgCl2 in-house PCR reaction buffer (Appendix A5.1), 6 
U of Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT, 24 U/µl), 10 U 
RNase inhibitor (RNASin, 40 U/µl), 10 µl of extracted RNA and the final volume made 
up to 50 µl. The Biometra thermal cycler (Biomedizinische Analytik, GmbH, Göttingen, 
Germany)  was used with the cycling conditions described above (section 3.7.1). This 
was followed by the nested PCR using 5.0 µl of the first round PCR products with the 
ORF1 inner sense and antisense primers (Table 3.1). The nested PCR reaction mixture 
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was the same as the first round PCR reaction mixture with the exception of AMV RT and 
RNAsin in a final volume of 100 µl made up with distilled water. The same cycling 
conditions used for the first round PCR were used for the nested PCR except for the RT 
step. Five microlitres of the nested PCR products were analyzed on a 1 % agarose gel by 
electrophoresis as described in section 3.3.4.  
 
The first and second round PCR reaction mixtures for amplifying the 3’-end of ORF2 
was the same as for amplifying the ORF1 except that external and internal ORF2 primers 
(Table 3.1) were used, respectively with the Supertherm DNA polymerase and its 
corresponding 10X PCR reaction buffer (JMR Holdings, UK) at 15 mM MgCl2 
concentration. The GeneAmp thermal cycler (The Perkin Elmer Corporation, Norwalk, 
USA) was used with the following final cycling conditions: First round PCR - 43 °C for 
45 minutes (RT step), followed by 35 cycles of 94 °C for 45 seconds, 48 °C for 45 
seconds (annealing temperature) and 72 °C for 1 minute followed by a last elongation 
step at 72 °C  for 7 minutes. Thereafter, the nested PCR was initiated with 10 µl of the 
first round PCR products using the same cycling conditions as the first round PCR except 
for the RT step and the use of the ORF2 inner primers. Ten microlitres of the nested PCR 
products were analyzed on a 1 % agarose gel by electrophoresis as described in section 
3.3.4. 
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3.7.3 RT-PCR of older specimens 
 
  3.7.3.1 The SuperScript II RT-PCR system 
 
The PCR conditions described for amplifying ORF2 in section 3.7.2 above, using RNA 
from the Namibian specimens,  were applied to the 1983 Botswana sera specimens and 
were found to be non-ideal for these older less well preserved specimens. Thus primers 
were modified as follows: One primer, Mor-Sn (5’-ATA CCC TGG ATT ACC CTG C, 
nt 1835-1853), based on the sequence of the Moroccan isolate (GeneBank Accession no. 
AF065061) was used as both external and internal sense primer  (designed as described 
in section 3.7) and used with both the external antisense and internal antisense ORF2 
primers (Table 3.1) for first and second round PCR, respectively. The specimens were 
first clarified and ultracentrifuged as described in section 3.6.1 and reverse transcription 
was then performed with the SuperScript II Rnase H- Reverse Transcriptase (GIBCO 
BRL®, Life Technologies, Scotland) according to the manufacturer’s protocol using the 
GeneAmp thermal cycler (The Perkin Elmer Corporation, Norwalk, USA), because this 
enzyme is reputed to give superior amplification with degraded RNA specimens (Gerard 
et al., 1986). Briefly, the RT reaction was primed with 1.0 µl oligo(dT) (500 µg/ml) 
which was added to 10 µl RNA (final volume made up to 20 µl) and the reaction mixture 
heated to 70 ºC for 10 minutes and quick chilled on ice. The following were then added 
to each reaction: 4.0 µl 5X First Strand buffer, 2.0 µl of 0.1 M DTT and 1.0 µl of 10 mM 
dNTPs. Final volume was thus 27 µl, and tubes were incubated briefly at 42 ºC for 2 
minutes. Then, 1.0 µl of SuperScript II (200 U/µl) was added and the RT reaction 
performed at 42 ºC for 50 minutes. The enzyme was then inactivated by heating at 70 ºC 
for 15 minutes and the cDNA used as a template for PCR amplification. The thermal 
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cycling conditions were as follows: First round PCR: 43 ºC for 45 minutes, 35 cycles at 
94 ºC for 45 seconds, 48 ºC for 45 seconds and 72 ºC for 1 minute, and a final extension 
step at 72 ºC for 7 minutes. This was followed by a nested PCR, initiated with 10 µl of 
the first round PCR product and the same PCR cycling conditions as the first round PCR 
less the RT step. A 2.5 % Metaphore agarose gel mixed with 0.5 µg/ml EthBr (final 
concentration) was prepared (Appendix A2.1 and A2.3) and 10 µl of the PCR products 
were mixed with 1.0 µl bromophenol blue/xylenexyanol loading dye and analyzed by 
electrophoresis in TBE buffer at 100 V for one hour against the DNA molecular weight 
markers V and VIII. 
 
  3.7.3.2 Platinum Pfx DNA polymerase 
 
PCR using Platinum Pfx DNA polymerase enzyme (GIBCO BRL®, Life Technologies, 
Scotland) was also tried on the difficult Botswana specimens. The cDNA generated by 
using SuperScript II as described in section 3.7.3.1 was used. The Mor-Sn primer was 
used with ORF2 primers as described above. The Platinum Pfx DNA polymerase was 
used according to the manufacturer’s protocol. The reaction mixture consisted of 1.0 µl 
Platinum Pfx DNA polymerase (2.5 U/µl), 5.0 µl of 10X Pfx amplification buffer, 200 
µM  (final concentration) of each dNTP, 1.0 µl of 50 mM MgSO4, 10 µM ORF2 primers 
(Table 3.1), 10 µl template DNA, and the final volume made up to 50 µl with distilled 
water. The GeneAmp thermal cycler (The Perkin Elmer Corporation, Norwalk, USA) 
was used with the following cycling conditions: first round PCR: 94 °C for 2 minutes and 
35 cycles of 94 °C for 15 seconds, 48 °C for 30 seconds and 68 °C for 1 minute with a 
final extension step at 68 °C for 1 minute. Nested PCR was performed using 10 µl of the 
first round PCR products with exactly the same cycling conditions as the first round 
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PCR. The amplification products were analyzed on a Metaphore agarose gel as described 
in section 3.7.3.1 with the use of DNA molecular weight marker VIII. 
 
3.8 Sequencing of PCR products 
 
 3.8.1 Sequencing reaction 
 
Cycle sequencing of PCR positive products was performed using the ABI Prism 
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (The Perkin Elmer 
Corporation, California, USA) according to the manufacturer’s protocol. Briefly, 30     
ng/µl PCR product was mixed with 8.0 µl Terminator Ready Reaction Mix and 3.2 pmol 
of inner sense primer (Table 3.1) for forward reaction and the final volume made up to 20 
µl with distilled water. The reaction mixture was subjected to the following cycling 
conditions with the GeneAmp thermal cycler (The Perkin Elmer Corporation, Norwalk, 
USA): 25 cycles of 96 ºC for 10 seconds, 50 ºC for 5 seconds and 60 ºC for 4 minutes 
and maintained at 4 ºC after cycling.  
 
 3.8.2 Sequencing reaction purification 
 
The sequencing reaction was purified from excess dye terminators by using the Centri-
Sep Spin-Columns purification kit (Princeton Separations Inc., USA) according to the 
manufacturer’s protocol. Briefly, the dry gel columns were hydrated with 800 µl RNAse-
free water for at least 2 hours at room temperature. Excess water was allowed to drain by 
gravity flow followed by a 3,000 rpm spin for 2 minutes in a microcentrifuge. Twenty 
microliters of the dideoxy sequencing reaction mixture was added onto the hydrated gel 
column and centrifuged as above. Purified samples were then collected and dried in a 
vacuum centrifuge for one hour. The dried pellets were resuspended in 6 µl of loading 
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dye before loading onto a gel for sequencing. The automated sequencing was performed 
using the ABI PRISM 377 DNA Sequencer (The Perkin Elmer Corporation, California, 
USA). 
  
3.9 Molecular analysis of PCR products 
 
 3.9.1 Construction of Phylogenetic trees 
 
The nucleotide sequences were aligned using DNAMAN software (version 4.0, Lynnon 
BioSoft). Phylogenetic distances and phylogenetic trees were generated, for both regions, 
using the same software.  The robustness of the trees was determined by 100 bootstrap 
replicates of multiple-sequence alignments. Bootstrap values of greater than 70 % were 
regarded as providing evidence for a phylogenetic grouping (Muerhoff et al., 1997). The 
final graphical output of the trees was created using TREEVIEW software (Win32, 
version 1.6.1).  
 
 3.9.2 Construction of consensus sequences 
 
Nucleotide sequences were translated to amino acid sequences using DNASIS software 
(version 2.5). A consensus amino acid sequence was generated from the Namibian 
isolates and aligned against the published amino acid sequences using DNAMAN 
software (version 4.0, Lynnon BioSoft). Percentage amino acid homologies were 
calculated using  the same software.    
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    CHAPTER 4: RESULTS 
 
4.1 Plasmid DNA preparation and sequencing  
 
4.1.1 Comparison of four methods of plasmid DNA extraction 
 
The Nucleon plasmid DNA preparation kit (Amersham International plc, 
Buckinghamshire, England, section 3.3.3) gave very low yields of cloned plasmid DNA, 
estimated to be less than 0.05 µg/µl since the DNA could not be visualized by gel 
electrophoresis (section 3.3.4). Both the Wizard DNA purification kit (Promega 
Corporation, Madison, USA) and the High Pure plasmid purification and isolation kit  
(Roche Diagnostics Corporation, Mannheim, Germany) produced adequate amounts (< 
0.1 µg/µl) of plasmid DNA. The DNA was, however, found to be impure by gel 
electrophoresis analysis. The control DNA bands (Kaposi Sarcoma virus; Alagiozoglou 
et al., 2000) were visually clear and sharp compared with the plasmid DNA bands which 
were smudged in appearance. The plasmid DNA had to be subsequently purified by 
ethanol precipitation (section 3.3.5). The Qiagen plasmid purification kit  (QIAGEN, 
GmbH, Germany) included isopropanol precipitation and an ethanol wash and produced 
high yields (> 0.2 µg/µl) of pure plasmid DNA which gave clear sharp bands  when 
visualized by gel electrophoresis (section 3.3.4).   
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4.1.2 Characterization of the plasmid DNA  
 
The plasmid DNA was used as a positive control in the initial PCR optimization 
experiments. The plasmid DNA sequence was confirmed by sequencing and restriction 
enzyme digestion prior to using clinical material. The plasmid DNA was sequenced by 
using the Thermosequenase cycle sequencing kit (Amersham International plc, 
Buckinghamshire, England) as outlined in section 3.4.2 and was found to consist of a 
2,002 bp HEV insert cloned into the 2,922 bp pCR1000 vector. The HEV insert is from 
the nonstructural ORF1 region of the Pakistan Sar55 isolate, and constitutes most of the 
helicase region and all of the polymerase (RdRp) region.   
 
The restriction enzyme digestion performed using Hind III RE linearized the plasmid 
(Figure 4.1) since it has only one cutting site in the plasmid vector (1,163 bp; Figure 4.2), 
producing a band of about 5 kb after gel electrophoresis (Figure 4.1, lanes 4 and 6). Hind 
III digestion performed with a control plasmid (section 3.4.1) produced three clear bands, 
the uncut plasmid band of 3,690 bp, and the two cut plasmid bands of 2,867 and 823 bp 
(Figure 4.1, lane 2).  
 
The restriction enzyme digestions were also performed using Sac I and Sma I REs. The 
five bands of sizes 2,670; 1,029; 624; 599 and 510 bp produced after simultaneous Sac I 
and Sma I digestion and gel electrophoresis of the plasmid with insert are shown in 
Figure 4.3, lane 5 and explained in Figure 4.2 and legend. 
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       1           2   3          4         5         6      7  M 
7,743 
5,526 
4,254 
3,140 
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2,867 
823 
Figure 4.1 Electrophoretogram showing the linearized HEV plasmid vector (lanes 4 
and 6) after restriction enzyme digestion with Hind III restriction endonuclease. 
Lane 2 represents the Hind III digested control plasmid (consisting of a fragment of 
the Kaposi sarcoma virus inserted in the pMosblue vector, see text). The molecular 
weight marker IV (M) is in Lane 8. The HEV plasmid vector has a size of 4,924 bp 
and runs slightly ahead of the 5,526 bp band of the size marker as expected. Lanes 
1, 3, 5 and 7 are empty.    
4.2 PCR optimization  
 
 4.2.1 PCR optimization using plasmid DNA 
  
PCR optimizations with the plasmid DNA using the Supertherm DNA polymerase (JMR 
Holdings, UK) with the 10X Roche PCR reaction buffer (Roche Diagnostics 
Corporation, Manneheim, Germany), as described in section 3.5, produced the best 
results and the external primers were found to work optimally at an annealing 
temperature of 50 °C (section 3.5.1) as shown in Figure 4.4.   
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  MVI      2      MVII          4             5  
2,670 
1,029 
624 
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510 
Figure 4.3 Restriction enzyme digestion of the HEV plasmid vector with Sac I and 
Sma I restriction endonucleases (lane 5; see Fig. 4.2 for full explanation of sizes 
observed). Lanes 1 (MVI) and 3 (MVII) contain molecular weight markers VI and 
VII, respectively, and lanes 2 and 4 are empty.          
Figure 4.4 Electrophoretogram depicting ORF1 first round RT-PCR reactions 
using plasmid DNA at 8 different annealing temperatures (from 42 °C to 56 °C, 
shown above). Lane M is the molecular weight marker VI.  
  M       42      44     46      48      50      52      54       56 
 4.2.2 RT-PCR using clinical material   
 
 4.2.2.1 PCR evaluation for viral RNA amplification of ORF1  
 
Titration of magnesium ion concentration was performed with six different PCR reaction 
buffers (section 3.7.1) and it was observed that the in-house buffer containing a final 
concentration of 1.0 mM MgCl2 (Appendix A) produced the best PCR positive results as 
compared to the other buffers and gave an amplicon with the expected band size of 559 
bp (Figures 4.5(a) and 4.5(b); see paragraph 3.7.2 for ORF1 final reaction conditions for 
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  6287     6293 
MVI    1      2      3      4      5      6     7      1      2      3      4     5       6     7 
(a) 
  8174     6255 
MVI   1       2      3      4      5      6      7     1      2      3       4      5      6      7 
(b) 
Figure 4.5 (a) and (b). Viral RNA isolated from 4 specimens were reverse transcribed 
and amplified in the ORF1 region with 6 different MgCl2 titration buffers. Lanes 1, 
2, 3 and 4 from both figures represent the in-house buffers containing 1.0 mM, 1.5 
mM, 2.0 mM and 2.5 mM MgCl2 final concentrations, respectively. Lanes 5 and 6 
(both figures) represent the 10X Supertherm reaction buffer and the 10X PCR 
reaction buffer (Roche) both with 1.5 mM MgCl2, respectively.  Lane MVI (both 
figures) represent the molecular weight marker VI and lanes 7 (both figures) 
contain water controls.  
653 
517 
517 
653 
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clinical specimens). 
RNA was amplified from 9.1 % of the specimens using ORF1 PCR. Amplified fragments 
were obtained from 7/74 stool specimens and 8/90 sera. While this region may be useful 
for diagnostic PCR, to compare our data with other African data, another region of the 
HEV genome was also targeted for PCR amplification. 
 
 4.2.2.2 PCR evaluation for viral RNA amplification of ORF2 
 
A region towards the carboxy terminal end of ORF2 was the next target for PCR 
amplification of viral RNA from clinical specimens. Primers were designed for this 
region (section 3.7, Table 3.1) and the PCR test was optimized (sections 3.7.1). The 1995 
Namibian specimens were used to amplify the 3’-end of ORF2 (section 3.7.1 and 3.7.2). 
It was observed that the Supertherm PCR reaction buffer consisting of 1.5 mM MgCl2 
together with RT-PCR at an annealing temperature of 48 °C produced the best results 
(optimization experiment not shown). An example of ORF2 PCR positive stool 
specimens analyzed by gel electrophoresis is shown in Figure 4.6. These PCR conditions 
were used to amplify 14 stool and 5 sera specimens. Five stool specimens (5/14) 
produced PCR positive results (35.7 %) and none from the 5 sera specimens.  
 
When the older (1983) Botswana specimens were used for PCR amplification of the 3’-
end of ORF2 no positive results were observed despite using specific reagent kits for 
amplifying problematic templates (section 3.7.3).   
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      M          1         2        3         4           C1       C2      M  
Figure 4.6 Electrophoretogram showing results for ORF2 nested RT-PCR of four 
specimens in lanes 1 to 4. Lane M represents the molecular weight marker VIII, C1 
and C2 are the negative water controls for first round PCR and nested PCR, 
respectively.  
900 
692 
4.3  Sequencing of PCR products 
 
Figure 4.7 shows a representative example of a sequencing electrophoretogram as output 
from the automated sequencing system which separates sets of fragments specifically 
terminated with either dideoxy thymidine (ddTTP), dideoxy adenosine (ddATP), dideoxy 
cytidine (ddCTP) and dideoxy guanosine (ddGTP). The fragments are distinguished by 
different fluorescent labels, where ddATP is green, ddTTP is red, ddGTP is black and 
ddCTP is blue (Figure 4.7). Where the software cannot clearly distinguish between 
different fragments, the ambiguous nucleotide is represented by an “N”. Although 
polymerases have a one in 5,000 error rate, errors at the same spot do not occur 
sufficiently often to affect signal intervals. Low signals can indicate low amounts of the 
specific PCR product or contamination by unspecific or primer dimer products. After 
electrophoresis, the computer identifies the dideoxynucleoside which terminates each 
oligonucleotide by identifying its characteristic spectrum. Thus, each colour peak in 
Figure 4.7 represents the specific nucleotide that was recognised at each position in the 
gel. Below the graph is the nucleotide sequence represented by the peaks as interpreted 
by the computer.   
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Figure 4.7 A representative graph showing the colour spectrum of each of the four 
nucleotides obtained from the ABI 377 sequencer. 
4.4 Phylogenetic analysis of the carboxy terminal (3’) end of ORF2 
 
 4.4.1 Nucleotide sequence analysis of ORF2 3’ end 
 
To determine the relationship between the Namibian isolates and other known HEV 
isolates within the ORF2 region, sequence data from four representative Namibian 
isolates (7798, 7801, 7948 and 8039) were aligned and compared to some of the global 
isolates (Table 4.1), over a 451 bp region of ORF2 positioned from 1,307 to 1,757 bp 
towards the carboxy terminal end of HEV genome. The nucleotide alignment is shown in 
Figure 4.8.  
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Table 4.1 HEV sequences used for ORF2 analysis. 
Name    GenBank   Reference 
    Accession No.  
      
82a-Burma   M73218  Tam et al. (1991) 
83-Chad T3   U62121  van Cuyck-Gandre et al. (1997) 
87-China-Xinjiang  D11092  Aye et al. (1992) 
87-China-Hebei  M94177  Bi et al. (1993)   
87-China-K52  L25595  Yin et al. (1994) 
87-China-Uigh179  D11093  Unpublished  
93-Egypt   AF051351  Tsarev et al. (1999) 
94-Egypt   AF051352  Tsarev et al. (1999) 
92-Fulminant (India?) X98292  Donati et al. (1997) 
90-India-Hyderabad  AF076239  Panda et al. (1995) 
93-India-Madras  X99441  Unpublished data 
87-Mexico   M74506  Huang et al. (1992) 
94-Morocco   AF065061  Meng et al. (1999) 
89-Myanmar   D10330  Aye et al. (1993)  
83-Namibia   AF105021  He et al. (2000) 
95-Namibia-7798  AY370686  Maila et al. (2004) 
95-Namibia-7801  AY370687  Maila et al. (2004) 
95-Namibia-7948  AY370688  Maila et al. (2004) 
95-Namibia-8039  AY370689  Maila et al. (2004)     
92-Nepal-TK15/92  AF051830  Gouvea et al. (1998) 
97/98-Nigeria-1  AF172999  Buisson et al. (2000) 
97/98-Nigeria-4  AF173000  Buisson et al. (2000) 
97/98-Nigeria-5  AF173001  Buisson et al. (2000) 
97/98-Nigeria-6  AF173230  Buisson et al. (2000) 
97/98-Nigeria-7  AF173231  Unpublished 
98-Nigeria-9   AF173232   Buisson et al. (2000)  
88-Pakistan-Abb-2B  AF185822  van Cuyck-Gandre et al. (1999)  
87-Pakistan-SAR-55  M80581  Tsarev et al. (1992) 
T1-China   AJ272108  Wang et al. (2000)  
95-USA-1   AF060668  Schlauder et al. (1998) 
95-USA-2   AF060669  Erker et al. (1999) 
 
aYear of isolation. 
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     1316      1326   1336      1346   1356      1366 
7798            CACGCGTGGTTATTCAGGATTATGACAATCAGCACGAGCAGGACCGCCCCACCCCCTCAC 
7801            CACGCGTGGTTATTCAGGATTATGACAATCAGCACGAGCAGGACCGCCCCACCCCCTCAC 
7948            CACGCGTGGTTATTCAGGATTATGACAATCAGCACGAGCAGGACCGCCCCACCCCCTCAC 
8039            CACGCGTGGTTATTCAGGATTATGACAATCAGCACGAGCAGGACCGCCCCACCCCCTCAC 
Mexico          CGCGTGTGGTCATTCAGGATTATGACAACCAGCATGAGCAGGATCGGCCCACCCCGTCGC 
ChadT3          CCCGTGTAGTTATCCAGGACTATGACAACCAACATGAGCAAGACCGACCGACACCTTCCC 
94Egypt         CCCGAGTAGTTATCCAGGACTATGACAACCAACATGAGCAAGATCGGCCGACACCTTCCC 
Morocco         CTCGTGTAGTCATCCAGGATTATGACAATCAGCATGAGCAGGACCGTCCGACACCTTCCC 
China-Xinjiang  CTCGTGTAGTTATTCAGGATTATGACAACCAACATGAGCAGGACCGACCGACACCTTCCC 
Fulminant       CTCGTGTGGTCATTCAGGATTATGATAACCAACATGAGCAAGATCGGCCGACACCTTCTC 
Pakistan-SAR-55 CCCGTGTAGTTATTCAGGATTATGACAACCAACATGAGCAGGACCGACCGACACCTTCCC 
Burma           CTCGTGTGGTTATTCAGGATTATGATAACCAACATGAACAAGATCGGCCGACGCCTTCTC 
Pakistan-Abb-2B CTCGTGTGGTTATTCAGGACTATGATAACCAACATGAACAGGACCGGCCGACGCCTTCGC 
Nepal           CTCGTGTGGTTATTCAGGATTATGATAACCAACATGAACAAGACCGGCCGACACCTTCTC 
India-Madras    CTCGTGTGGTTATTCAGGATTATGACAATCAACATGAACAAGACCGGCCGACGCCTTCTC 
T1              CCCGTGTGGTTATTCAGGATTATGACAACCAACATGAGCAAGATCGTCCCACTCCCTCCC 
US-1            CCCGTGTGGTTATCCAGGATTATGATAACCAGCACGAACAAGATCGACCTACCCCGTCAC 
US-2            CCCGTGTGGTTATCCAGGATTATGATAACCAGCANGAGCAAGACCGACCTACTCCGTCAC 
                * ** ** ** ** ***** ***** ** ** ** ** ** ** ** ** ** ** ** * 
 
     1376      1386      1396      1406   1416      1426 
7798            CTGCACCGTCCCGGTCCTTTTCTGTCCTCCGTGCAAATGATGTGCTTTGGCTGTCTCTCA 
7801            CTGCACCGTCCCGGCCCTTTTCTGTCCTCCGTGCAAATGATGTGCTTTGGCTGTCTCTTA 
7948            CTGCACCGTCCCGGCCCTTTTCTGTCCTCCGTGCAAATGATGTGCTTTGGCTGTCTCTTA 
8039            CTGCACCGTCCCGGCCCTTTTCTGTCCTCCGTGCAAATGATGTGCTTTGGCTGTCTCTTA 
Mexico          CTGCGCCATCTCGGCCTTTTTCTGTTCTCCGAGCAAATGATGTACTTTGGCTGTCCCTCA 
ChadT3          CAGCCCCGTCGCGCCCTTTCTCTGTCCTTCGGGCTAATGATGTGCTTTGGCTTTCTCTCA 
94Egypt         CAGCCCCGTCGCGCCCTTTCTCTGTCCTTCGGGCCAACGATGTGCTTTGGCTCTCTCTCA 
Morocco         CAGCCCCGTCTCGCCCTTTTTCTGTTCTCCGGGCCAATGATGTGCTTTGGCTCTCTCTCA 
China-Xinjiang  CAGCCCCATCGCGCCCTTTTTCTGTCCTCCGAGCTAATGATGTGCTTTGGCTTTCTCTCA 
Fulminant       CAGCCCCATCGCGCCCTTTTTCTGTCCTCCGAGCTAATGATGTGCTTTGGCTTTCTCTCA 
Pakistan-SAR-55 CAGCCCCATCGCGTCCTTTTTCTGTCCTCCGAGCTAACGATGTGCTTTGGCTTTCTCTCA 
Burma           CAGCCCCATCGCGCCCTTTCTCTGTCCTTCGAGCTAATGATGTGCTTTGGCTCTCTCTCA 
Pakistan-Abb-2B CAGCTCCATCGCGCCCTTTTTCTGTCCTTCGAGCTAATGATGTGCTTTGGCTCTCTCTCA 
Nepal           CAGCCCCGTCGCGCCCTTTCTCTGTTCTTCGAGCTAATGATGTGCTTTGGCTCTCTCTCA 
India-Madras    CAGCCCCATCGCGCCCTTTCTCTGCCCTTCGAGCTAACGATGTGCTTTGGCTCTCTCTCA 
T1              CTGCTCCCTCTCGTCCATTTTCTGTTCTTCGTGCTAATGATGTGCTTTGGCTTTCACTTA 
US-1            CTGCCCCCTCCCGCCCTTTCTCAGTTCTTCGTGCCAATGATGTTTTGTGGCTCTCTCTCA 
US-2            CTGCCCCCTCTCGCCCCTTCTCAGTTCTTCGTGCCAATGATGTTTTGTGGCTTTCCCTCA 
                * ** ** ** **  * ** ** *  ** ** ** ** *****  * ***** ** ** * 
 
     1436      1446   1456      1466   1476      1486 
7798            CTGGGGCCGAGTATGACCAATCTACGTACGGGTCGTCCACCGGCCCGGTTTATGTCTCGG 
7801            CTGGGGCCGAGTATGACCAATCTACGTACGGGTCGTCCACCGGCCCGGTTTATGTCTCGG 
7948            CTGGGGCCGAGTATGACCAGTCTACGTACGGGTCGTCCACCGGCCCGGTTTATGTCTCGG 
8039            CTGGGGCCGAGTATGACCAGTCTACGTACGGGTCGTCCACCGGCCCGGTTTATGTCTCGG 
Mexico          CTGCAGCCGAGTATGACCAGTCCACTTACGGGTCGTCAACTGGCCCGGTTTATATCTCGG 
ChadT3          CCGCTGCCGAGTATGACCAGTCCACCTACGGCTCCTCGACTGGCCCAGTCTATGTCTCTG 
94Egypt         CCGCTGCCGAGTATGACCAGTCCACCTATGGCTCCTCGACTGGCCCAGTCTATGTTTCTG 
Morocco         CTGCTGCTGAGTATGATCAGTCCACCTATGGCTCTTCTACTGGCCCAGTCTATGTCTCCG 
China-Xinjiang  CCGCTGCCGAGTATGACCAGTCCACTTACGGCTCTTCGACCGGCCCAGTCTATGTCTCTG 
Fulminant       CCGCTGCCGAGTATGACCAGTCCACTTACGGTTCTTCGACCGGCCCAGTCTATGTTTCTG 
Pakistan-SAR-55 CCGCTGCCGAGTATGACCAGTCCACTTACGGCTCTTCGACCGGCCCAGTCTATGTCTCTG 
Burma           CCGCTGCCGAGTATGACCAGTCCACTTATGGCTCTTCGACTGGCCCAGTTTATGTTTCTG 
Pakistan-Abb-2B CCGCTGCCGAGTATGACCAATCCACTTATGGCTCTTCGACTGGCCCAGTTTATGTCTCTG 
Nepal           CCGCTGCCGAGTATGACCAGTCCACCTATGGCTCTTCGACTGGCCCAGTTTATGTTTCTG 
India-Madras    CTGCTGCCGAGTACGACCAGTCCACTTATGGCTCTTCGACTGGCCCAGTTTATGTTTCTG 
T1              CTGCTGCTGAGTATGATCAAACGACTTATGGCTCCTCTACCAACCCTATGTATGTTTCTG 
US-1            CTGCCGCTGAGTACGNCCAGACCACGTATGGGTCGTCCACCAACCCTATGTATGTCTCTG 
US-2            CTGCCGCTGAGTATGACCAGACTACGTATGGGTCGTCCACCAACCCTATGTATGTCTCTG 
                * *  ** ***** *  **  * ** ** ** ** ** **   ***  * *** * ** * 
84 
 
     1496      1506   1516      1526   1536      1546 
7798            ATAGTGTGACCTTGGTGAATGTAGCGACCGGCGCGCAGGCCGTAGCCCGGTCGCTCGACT 
7801            ATAGTGTGACCTTGGTGAATGTAGCGACCGGCGCGCAGGCCGTAGCCCGGTCGCTCGACT 
7948            ATAGTGTGACCTTGGTGAATGTAGCGACCGGCGCGCAGGCCGTAGCCCGGTCGCTCGACT 
8039            ATAGTGTGACCTTGGTGAATGTAGCGACCGGCGCGCAGGCCGTAGCCCGGTCGCTCGACT 
Mexico          ACAGCGTGACTTTGGTGAATGTTGCGACTGGCGCGCAGGCCGTAGCCCGATCGCTTGACT 
ChadT3          ACTCTGTGACCTTGGTCAATGTTGGGACCGGCGCGCAGGCCGTTGCTCGGTCGCTCGACT 
94Egypt         ACTCCGTGACCTTGGTCAACGTTGCGACCGGCGCGCAGGCCGTTGCTCGGTCGCTCGATT 
Morocco         ACTCTGTGACCTTGGTCAATGTTGCGACCGGCGCGCAGGCCGTTGCTCGGTCGCTTGACT 
ChinaXin        ACTCTGTGACCTTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCACTCGACT 
Fulminant       ACTCTGTGACCCTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCGCTTGACT 
PakiSar55       ACTCTGTGACCTTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCACTCGACT 
BurmaB1         ACTCTGTGACCTTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCGCTCGATT 
PakisAbb        ACTCTGTGACCTTGGTTAATGTCGCGACCGGCGCGCAGGCCGTTGCCCGGTCGCTCGATT 
Nepal           ACTCTGTGACCTTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCGCTCGATT 
IndiMadras      ACTCTGTGACCTTGGTTAATGTTGCGACCGGCGCGCAGGCCGTTGCCCGGTCGCTCGATT 
T1              ACACTGTTACATTTGTTAACGTAGCGACTGGTGCCCAGGGGGTTTCGCGCTCTCTGGATT 
US-1            ATACAGTCACGCTTGTTAATGTAGCCACTGGTGCTCAGGCTGTTGCCCGCTCTCTTGACT 
US-2            ACACAGTTACGCTTGTTAATGTGGCTACTGGTGCTCAGGCTGTTGCCCGCTCCCTTGATT 
                *    ** **  * ** ** ** *  ** ** ** ****  **  * ** ** ** ** * 
 
     1556      1566   1576      1586   1596      1606
  
7798            GGTCCAAGGTTACTCTTGACGGGCGGCCCTTACCTACTATTGAACAATATTCTAAGTCAT 
7801            GGTCCAAGGTTACTCTTGACGGGCGGCCCTTACCTACTATTGAACAATATTCTAAGTCAT 
7948            GGTCCAAGGTTACTCTTGACGGGCGGCCCTTACCTACTATTGAACAATATTCTAAGTCAT 
8039            GGTCCAAGGTTACTCTTGACGGGCGGCCCTTACCTACTATTGAACAATATTCTAAGTCAT 
Mexico          GGTCCAAAGTCACCCTCGACGGGCGGCCCCTCCCGACTGTTGAGCAATATTCCAAGACAT 
ChadT3          GGACCAAGGTCACACTCGATGGTCGCCCTCTATCTACTATTCAGCAGTATTCGAAGACTT 
94Egypt         GGACTAAGGTCACGCTCGATGGTCGCCCCCTTTCTACCATTCAGCAGTACTCGAAGACTT 
Morocco         GGACTAAGGTCACACTTGATGGCCGCCCTCTTTCTACTATCCAGCAGTATTCGAAGACTT 
ChinaXin        GGACCAAGGTCACACTTGATGGTCGCCCCCTTTCCACCATCCAGCAGTATTCAAAGACCT 
Fulminant       GGACCAAGGTCACACTTGATGGTCGCCCCCTCTCCACCATCCAGCAGTATTCAAAGACCT 
PakiSar55       GGACCAAGGTCACACTTGATGGTCGCCCCCTTTCCACCATCCAGCAGTATTCAAAGACCT 
BurmaB1         GGACCAAGGTCACACTTGACGGTCGCCCCCTCTCCACCATCCAGCAGTACTCGAAGACCT 
PakisAbb        GGACCAAGGTCACACTTGACGGCCGCCCCCTCTCCACCATCCAGCAGTACTCGAAGACCT 
Nepal           GGACCAAGGTCACACTTGATGGCCGCCCTCTCTCCACCATCCAGCAGTACTCGAAGACCT 
IndiMadras      GGACCAAGGTCACACTTGACGGTCGCCCTCTCTCCACCATCCAGCAGTACTCGAAGACCT 
T1              GGTCTAAGGTCACTCTCGATGGCCGTCCACTCACCACCATCCAGCAGTATTCTAAGACTT 
US-1            GGTCTAAAGTTACTCTGGATGGTCGCCCTCTTACTACCATTCAGCAGTATTCTAAGAAAT 
US-2            GGTCTAAAGTTACTCTGGACGGCCGCCCCCTTACTACCATTCAGCAGTATTCTAAGACAT 
                ** * ** ** ** ** ** ** ** **  *  * **  *  * ** ** ** ***   * 
 
     1616      1626   1636      1646      1656      1666 
7798            TCTTTGTGTTGCCCCTTCGTGGTAAGCTCTCTTTTTGGGAGGCCGGTACAACGAAAGCGG 
7801            TCTTTGTGTTGCCCCTTCGTGGTAAGCTCTCTTTTTGGGAGGCCGGTACAACGAAAGCGG 
7948            TCTTTGTGTTGCCCCTCCGTGGTAAGCTCTCTTTTTGGGAGGCCGGTACAACGAAAGCGG 
8039            TCTTTGTGTTGCCCCTTCGTGGTAAGCTCTCTTTTTGGGAGGCCGGTACAACGAAAGCGG 
Mexico          TCTTTGTGCTCCCCCTTCGTGGCAAGCTCTCCTTTTGGGAGGCCGGCACAACAAAAGCAG 
ChadT3          TCTTCGTCCTGCCGCTTCGTGGCAAGCTCTCCTTCTGGGAGGCGGGTACTACTAAAGCCG 
94Egypt         TCTTTGTCCTGCCCCTCCGTGGCAAGCTCTCCTTTTGGGAGGCAGGTACTACTAAAGCCG 
Morocco         TCTTTGTCCTGCCGCTTCGTGGTAAACTTTCCTTCTGGGAGGCAGGTACCACTAAAGCCG 
ChinaXin        TCTTTGTCCTGCCGCTCCGCGGTAAGCTCTCCTTTTGGGAGGCAGGTACTACTAAAGCCG 
Fulminant       TCTTCGTCCTGCCGCTCCGCGGTAAGCTCTCCTTCTGGGAGGCAGGTACCACTAAGGCCG 
PakiSar55       TCTTTGTCCTGCCGCTCCGCGGTAAGCTCTCCTTTTGGGAGGCAGGAACTACTAAAGCCG 
BurmaB1         TCTTTGTCCTGCCGCTCCGCGGTAAGCTCTCTTTCTGGGAGGCAGGCACAACTAAAGCCG 
PakisAbb        TCTTTGTCCTGCCGCTCCGCGGTAAGCTCTCTTTCTGGGAGGCAGGCACAACTAAAGCCG 
Nepal           TCTTTGTCCTGCCGCTCCGCGGAAAGCTCTCTTTCTGGGAGGCAGGCACAACTAAGGCCG 
IndiMadras      TCTTTGTCCTGCCGCTCCGCGGCAAGCTCTCTTTCTGGGAGGCAGGTACAACTAAGGCCG 
T1              TCTATGTCTTGCCCCTTCGTGGTAAGCTTTCCTTTTGGGAGGCCGGCACCACTAAAGCCG 
US-1            TTTATGTTCTCCCGCTTCGNGGGAAGCTGTCCTTTTGGGAGGCTGGTACGACCAAGGCCG 
US-2            TTTATGTTCTCCCGCTCCGCGGGAAGCTGTCCTTTTGGGAGGCTGGCACGACTAAGGCCG 
                * *  **  * ** ** ** ** ** ** ** ** ******** ** ** ** ** ** * 
85 
 
     1676      1686   1696      1706   1716      1726 
7798            GTTACCCCTATAATTACAATACCACTGCTAGTGACCAGATTCTGATCGAGAATGCGGGCG 
7801            GTTACCCCTATAATTACAACACCACTGCTAGTGACCAGATTCTGATCGAGAATGCGGCCG 
7948            GTTACCCCTATAATTACAACACCACTGCTAGTGACCAGATTCTGATCGAGAATGCGGCCG 
8039            GTTACCCCTATAATTACAACACCACTGCTAGTGACCAGATTCTGATCGAGAATGCGGCCG 
Mexico          GTTATCCTTATAATTATAATACTACTGCTAGTGACCAGATTCTGATTGAAAATGCTGCCG 
ChadT3          GGTACCCTTATAATTATAATACCACTGCTAGCGACCAATTGCTCATCGAGAACGTCGCTG 
94Egypt         GGTACCCTTATAATTACAATACCACTGCTAGCGACCAATTGCTTATCGAGAACGCCACCG 
Morocco         GGTACCCTTACAATTATAATACTACTGCTAGTGACCAACTGCTCGTTGAGAATGCCGCCG 
ChinaXin        GGTACCCTTATAATTATAACACCACTGCTAGTGACCAACTGCTCGTTGAGAATGCCGCTG 
Fulminant       GGTACCCCTATAATTATAATACCACTGCTAGCGATCAACTGCTTATTGAGAATGCCGCCG 
PakiSar55       GGTACCCTTATAATTATAACACCACTGCTAGTGACCAACTGCTCGTTGAGAATGCCGCTG 
BurmaB1         GGTACCCTTATAATTATAACACCACTGCTAGCGACCAACTGCTTGTCGAGAATGCCGCCG 
PakisAbb        GGTACCCTTATAATTATAATACCACTGCTAGCGACCAACTGCTCGTCGAGAATGCCGCCG 
Nepal           GGTACCCTTATAATTACAACACCACTGCTAGCGGCCAACTGCTTGTCGAGAATGCCGCCG 
IndiMadras      GGTACCCTTATAATTATAATACCACTGCTAGCGACCAACTGCTTGTCGAGAATGCCGCCG 
T1              GCTACCCTTATAATTATAACACTACTGCTAGTGACCAGATCCTGATTGAGAATGCAGCGG 
US-1            GCTACCCGTATAATTATAATACCACTGCTAGTGACCAAATTTTGATTGAGAACGCGGCCG 
US-2            GCTACCCTTACAATTATAATACTACCGCTAGTGACCAAATTTTGATTGAGAATGCGGCCG 
                * ** ** ** ***** ** ** ** ***** *  **  *  *  * ** ** *     * 
 
     1736      1746   1756 
7798            GGCACCGAGTCTCCATTTCGACCTATACCAC 
7801            GCCACCGAGTCTCCATTTCGACCTATACCAC 
7948            GCCACCGAGTCTCCATTTCGACCTATACCAC 
8039            GCCACCGAGTCTCCATTTCGACCTATACCAC 
Mexico          GCCATCGGGTCGCCATTTCAACCTATACCAC 
ChadT3          GGCATCGGGTGGCTATTTCCACCTATACCAC 
94Egypt         GGCATCGGGTGGCTATTTCTACTTACACTAC 
Morocco         GGCACCGGGTGGCTATTTCCACCTACACCAC 
ChinaXin        GGCATCGGGTTGCTATTTCCACTTACACCAC 
Fulminant       GGCATCGGGTTGCTATTTCCACTTACACCAC 
PakiSar55       GGCATCGGGTTGCTATTTCCACCTACACTAC 
BurmaB1         GGCACCGGGTCGCTATTTCCACTTACACCAC 
PakisAbb        GGCACCGGGTTGCTATTTCCACTTACACCAC 
Nepal           GGCACCGGGTTGCTATCTCCACTTACACCAC 
IndiMadras      GGCACCGGGTTGCTATCTCCACTTACACCAC 
T1              GCCACCGAGTTTGCATCTCTACCTACACTAC 
US-1            GTCACCGTGTCGCCATTTCTACTTATACCAC 
US-2            GCCACCGTGTCGCTATTTCCACCTATACCAC 
                * ** ** **    ** ** ** ** ** ** 
Figure 4.8 Nucleotide alignment of global HEV isolates against the Namibian 
sequences from position 1,307 to 1,757 of the ORF2 region (nucleotide numbering 
with respect to the HPEGENSA isolate, GenBank Accession no. L08816). The 
asterisks denote conserved nucleotide positions.    
A bootstrapped tree was constructed from 100 replicates of the nucleotide alignment and 
rooted on the Chinese isolate, T1 (Figure 4.9). The phylogenetic tree grouped the isolates 
into the four conventional genotypes (nomenclature according to Wang et al., 2000 and 
Widdowson et al., 2003). Afro-Asian isolates clustered in genotype I, the Mexican 
isolate and the newly defined 1995 Namibian isolates in genotype II, the United States 
isolates in genotype III and the Chinese isolate T1, in genotype IV. These four genetic 
86 
Figure 4.9 Phylogenetic tree of HEV isolates from position 1,307 to 1,757 of the 
ORF2 region (numbering according to the HPEGENSA sequence, GenBank 
Accession no. L08816). The tree shows the conventional segregation of HEV isolates 
into four genotypes (I-IV) and it is rooted with the T1 sequence. Clades are labeled 
according to the nomenclature of Wang et al., 2000. Bootstrap values for the most 
robust groupings are shown.  
clusters are consistent with previous studies. The four 1995 Namibian sequences (bold 
numbers in Figure 4.9) shared a nucleotide identity of between 98.4 and 99.8 % and were 
85.8-86.3 % similar to the Mexican isolate (Table 4.2). The 95-Namibian sequences were 
only 77.6-79.6 % similar to other African isolates (Table 4.2).  
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Nigerian HEV isolates, from sporadic cases that were observed during 1997-1998, were 
previously also shown to cluster together with the 1987 Mexican isolate (Buisson et al., 
2000). To compare the four 1995 Namibian sequences with the Nigerian isolates and the 
1983 Namibian isolate a nucleotide alignment was constructed from a 180 bp region 
where the sequences overlap (Figure 4.10).  
 
     1586      1596   1606      1616   1626      1636 
7798            TACCTACTATTGAACAATATTCTAAGTCATTCTTTGTGTTGCCCCTTCGTGGTAAGCTCT 
7801            TACCTACTATTGAACAATATTCTAAGTCATTCTTTGTGTTGCCCCTTCGTGGTAAGCTCT 
7948            TACCTACTATTGAACAATATTCTAAGTCATTCTTTGTGTTGCCCCTCCGTGGTAAGCTCT 
8039            TACCTACTATTGAACAATATTCTAAGTCATTCTTTGTGTTGCCCCTTCGTGGTAAGCTCT 
Nigeria-1       TCCCTACTATTGAGCAGTACTCCAAGTCATTCTTTGTGTTGCCCCTTCGCGGTAAGCTCT 
Nigeria-9       TCCCTACTATTGAGCAGTATTCCAAGTCATTCTTTGTGTTGCCCCTTCGCGGTAAGCTCT 
Mexico          TCCCGACTGTTGAGCAATATTCCAAGACATTCTTTGTGCTCCCCCTTCGTGGCAAGCTCT 
ChadT3          TATCTACTATTCAGCAGTATTCGAAGACTTTCTTCGTCCTGCCGCTTCGTGGCAAGCTCT 
83Namibia       TATCTACGATTCAGCAGTATTCGAAGACTTTCTTCGTCCTGCCGCTTCGTGGCAAGCTCT 
94Egypt         TTTCTACCATTCAGCAGTACTCGAAGACTTTCTTTGTCCTGCCCCTCCGTGGCAAGCTCT 
Morocco         TTTCTACTATCCAGCAGTATTCGAAGACTTTCTTTGTCCTGCCGCTTCGTGGTAAACTTT 
China-Xinjiang  TTTCCACCATCCAGCAGTATTCAAAGACCTTCTTTGTCCTGCCGCTCCGCGGTAAGCTCT 
Fulminant       TCTCCACCATCCAGCAGTATTCAAAGACCTTCTTCGTCCTGCCGCTCCGCGGTAAGCTCT 
Pakistan-SAR-55 TTTCCACCATCCAGCAGTATTCAAAGACCTTCTTTGTCCTGCCGCTCCGCGGTAAGCTCT 
Burma           TCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCCTGCCGCTCCGCGGTAAGCTCT 
Pakistan-Abb-2B TCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCCTGCCGCTCCGCGGTAAGCTCT 
Nepal           TCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCCTGCCGCTCCGCGGAAAGCTCT 
India-Madras    TCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCCTGCCGCTCCGCGGCAAGCTCT 
T1              TCACCACCATCCAGCAGTATTCTAAGACTTTCTATGTCTTGCCCCTTCGTGGTAAGCTTT 
US-1            TTACTACCATTCAGCAGTATTCTAAGAAATTTTATGTTCTCCCGCTTCGNGGGAAGCTGT 
US-2            TTACTACCATTCAGCAGTATTCTAAGACATTTTATGTTCTCCCGCTCCGCGGGAAGCTGT 
                *  * **  *  * ** ** ** ***   ** *  **  * ** ** ** ** ** ** * 
 
     1646      1656   1666      1676   1686      1696 
7798            CTTTTTGGGAGGCCGGTACAACGAAAGCGGGTTACCCCTATAATTACAATACCACTGCTA 
7801            CTTTTTGGGAGGCCGGTACAACGAAAGCGGGTTACCCCTATAATTACAACACCACTGCTA 
7948            CTTTTTGGGAGGCCGGTACAACGAAAGCGGGTTACCCCTATAATTACAACACCACTGCTA 
8039            CTTTTTGGGAGGCCGGTACAACGAAAGCGGGTTACCCCTATAATTACAACACCACTGCTA 
Nigeria-1       CTTTTTGGGAGGCTGGTACAACGAAAGCGGGCTACCCTTATAATTACAACACCACAGCTA 
Nigeria-9       CTTTTTGGGAGGCTGGTACAACGAAAGCGGGCTACCCTTATAATTACAACACCACAGCTA 
Mexico          CCTTTTGGGAGGCCGGCACAACAAAAGCAGGTTATCCTTATAATTATAATACTACTGCTA 
ChadT3          CCTTCTGGGAGGCGGGTACTACTAAAGCCGGGTACCCTTATAATTATAATACCACTGCTA 
83Namibia       CCTTCTGGGAGGCGGGTACCACTAAAGCCGGGTACCCTTATAATTATAATACTACTGCTA 
94Egypt         CCTTTTGGGAGGCAGGTACTACTAAAGCCGGGTACCCTTATAATTACAATACCACTGCTA 
Morocco         CCTTCTGGGAGGCAGGTACCACTAAAGCCGGGTACCCTTACAATTATAATACTACTGCTA 
China-Xinjiang  CCTTTTGGGAGGCAGGTACTACTAAAGCCGGGTACCCTTATAATTATAACACCACTGCTA 
Fulminant       CCTTCTGGGAGGCAGGTACCACTAAGGCCGGGTACCCCTATAATTATAATACCACTGCTA 
Pakistan-SAR-55 CCTTTTGGGAGGCAGGAACTACTAAAGCCGGGTACCCTTATAATTATAACACCACTGCTA 
Burma           CTTTCTGGGAGGCAGGCACAACTAAAGCCGGGTACCCTTATAATTATAACACCACTGCTA 
Pakistan-Abb-2B CTTTCTGGGAGGCAGGCACAACTAAAGCCGGGTACCCTTATAATTATAATACCACTGCTA 
Nepal           CTTTCTGGGAGGCAGGCACAACTAAGGCCGGGTACCCTTATAATTACAACACCACTGCTA 
India-Madras    CTTTCTGGGAGGCAGGTACAACTAAGGCCGGGTACCCTTATAATTATAATACCACTGCTA 
T1              CCTTTTGGGAGGCCGGCACCACTAAAGCCGGCTACCCTTATAATTATAACACTACTGCTA 
US-1            CCTTTTGGGAGGCTGGTACGACCAAGGCCGGCTACCCGTATAATTATAATACCACTGCTA 
US-2            CCTTTTGGGAGGCTGGCACGACTAAGGCCGGCTACCCTTACAATTATAATACTACCGCTA 
                * ** ******** ** ** ** ** ** ** ** ** ** ***** ** ** ** **** 
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     1706      1716   1726      1736   1746      1756 
7798            GTGACCAGATTCTGATCGAGAATGCGGGCGGGCACCGAGTCTCCATTTCGACCTATACCA 
7801            GTGACCAGATTCTGATCGAGAATGCGGCCGGCCACCGAGTCTCCATTTCGACCTATACCA 
7948            GTGACCAGATTCTGATCGAGAATGCGGCCGGCCACCGAGTCTCCATTTCGACCTATACCA 
8039            GTGACCAGATTCTGATCGAGAATGCGGCCGGCCACCGAGTCTCCATTTCGACCTATACCA 
Nigeria-1       GCGACCAGATTTTGATTGAGAATGCAGCCGGCCACCGAGTTGCTATTTCGACCTATACCA 
Nigeria-9       GCGATCAGATTTTGATCGAGAATGCAGCCGGCCACCGAGTTGCTATTTCGACCTATACCA 
Mexico          GTGACCAGATTCTGATTGAAAATGCTGCCGGCCATCGGGTCGCCATTTCAACCTATACCA 
ChadT3          GCGACCAATTGCTCATCGAGAACGTCGCTGGGCATCGGGTGGCTATTTCCACCTATACCA 
83Namibia       GCGACCAATTGCTTATCGAGAACGCCGCTGGGCATCGGGTGGCCATTTCTACTTATACCA 
94Egypt         GCGACCAATTGCTTATCGAGAACGCCACCGGGCATCGGGTGGCTATTTCTACTTACACTA 
Morocco         GTGACCAACTGCTCGTTGAGAATGCCGCCGGGCACCGGGTGGCTATTTCCACCTACACCA 
China-Xinjiang  GTGACCAACTGCTCGTTGAGAATGCCGCTGGGCATCGGGTTGCTATTTCCACTTACACCA 
Fulminant       GCGATCAACTGCTTATTGAGAATGCCGCCGGGCATCGGGTTGCTATTTCCACTTACACCA 
Pakistan-SAR-55 GTGACCAACTGCTCGTTGAGAATGCCGCTGGGCATCGGGTTGCTATTTCCACCTACACTA 
Burma           GCGACCAACTGCTTGTCGAGAATGCCGCCGGGCACCGGGTCGCTATTTCCACTTACACCA 
Pakistan-Abb-2B GCGACCAACTGCTCGTCGAGAATGCCGCCGGGCACCGGGTTGCTATTTCCACTTACACCA 
Nepal           GCGGCCAACTGCTTGTCGAGAATGCCGCCGGGCACCGGGTTGCTATCTCCACTTACACCA 
India-Madras    GCGACCAACTGCTTGTCGAGAATGCCGCCGGGCACCGGGTTGCTATCTCCACTTACACCA 
T1              GTGACCAGATCCTGATTGAGAATGCAGCGGGCCACCGAGTTTGCATCTCTACCTACACTA 
US-1            GTGACCAAATTTTGATTGAGAACGCGGCCGGTCACCGTGTCGCCATTTCTACTTATACCA 
US-2            GTGACCAAATTTTGATTGAGAATGCGGCCGGCCACCGTGTCGCTATTTCCACCTATACCA 
                * *  **  *  *  * ** ** *     ** ** ** **    ** ** ** ** ** * 
 
Figure 4.10 Nucleotide alignment of global HEV isolates, including 83-Namibian 
and 97/98-Nigerian isolates, against the Namibian sequences from position 1,577 to 
1,756 of the ORF2 region (numbering according to the HPEGENSA isolate, 
GenBank Accession no. L08816).   
A bootstrapped phylogenetic tree was constructed from 100 replicates of the alignment 
and rooted on the T1 isolate (Figure 4.11). The 95-Namibian sequences shared a 
nucleotide identity of between 97.8-100 %, were 88.9-91.1 % similar to the 97/98 
Nigerian isolates and 85.6-86.1 % similar to the Mexican isolate (Table 4.3), all in 
genotype II. The 95-Namibian sequences were only 77.8-78.9 % similar to the 83-
Namibian isolate (Table 4.3) in genotype I. Genotype I partitions into two geographical 
groupings with the African isolates clustering away from the Asian isolates. The 95-
Namibian sequences, however, group together, as a separate clade of genotype II and are 
most similar to the 97/98 Nigerian isolates. This analysis clearly distinguishes between 
strains of HEV responsible for the 1995 Namibian outbreak and other reported African 
strains.   
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Fig. 4.11 Phylogenetic tree of HEV isolates, including 83-Namibian and 97/98-
Nigerian isolates, from position 1,577 to 1,756 (nucleotide numbering with respect to 
the HPEGENSA isolate, GenBank Accession no. L08816) of the ORF2 region. The 
tree is rooted with the T1 sequence and clades are labeled according to the 
nomenclature of Wang et al., 2000. Bootstrap values for the most robust groupings 
are shown.  
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  4.4.2 Analysis of genetic distances within the 3’-end of ORF2 
 
The consensus sequence of the four 95-Namibian isolates was compared to 20 HEV 
isolates (used in Figure 4.9) over the 451 bp target region of ORF2, and the frequency of 
evolutionary distances were plotted for each 0.02 range between zero and 0.259 (Figure 
4.12). The three peaks of the histogram indicate that isolates within the same 
subgenotype are less than 4 % different from one another, genotypic groups differ by 
greater than 18 % and subgenotypes are defined between these two values. Therefore, the 
suitability of this subgenomic fragment for phylogenetic analysis is demonstrated by both 
bootstrap analysis and in the clear separation of type and subtype evolutionary distances 
in the histogram.   
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Figure 4.12 Histogram representing the distribution of genetic distances calculated 
for ORF2 region, from position 1,307 to 1,757 of the HEV genome. 
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 4.4.3 Amino acid analysis of ORF2 3’-end   
 
The consensus sequence of the four Namibian isolates was translated into a consensus 
amino acid sequence. To observe the relationship between Namibian amino acid 
sequences and other amino acid sequences from global isolates within the 3’-end of 
ORF2 region, the Namibian consensus amino acid sequence was compared to the 
deduced amino acid sequence of 14 GenBank isolates (Figure 4.13) based on the 451 bp 
target region. Unique, definitive amino acids common to the 95-Namibia consensus 
sequence only were observed at residues 477 (Alanine ‘A’ to Glycine ‘G’), 535 
(Threonine ‘T’ to Serine ‘S’) and 580 (‘A’ to ‘S’), and those common to both 95-
Namibia and Mexico were observed at residues 517 (‘T’ to ‘S’), 527 (‘S’ to Proline ‘P’) 
and 530 (Glutamine ‘Q’ to Glutamic acid ‘E’). Amino acid changes shared by genotype 
II isolates but not unique to this group were observed at residues 569 (Leucine ‘L’ to 
Isoleucine ‘I’) and 571 (Valine ‘V’ to ‘I’). The Mexican subgroup of genotype II is 
defined by unique amino acid changes at residues 494 (‘V’ to ‘I’) and 529 (‘I’ to ‘V’).  
 
      446       456    466       476    486       496 
Consensus       RVVIQDYDNQHEQDRPTPSPAPSRPFSVLRANDVLWLSLTGAEYDQSTYGSSTGPVYVSD      
Mexico          ----------------------------------------a----------------i--      
ChadT3          ----------------------------------------a-------------------      
94Egypt         ----------------------------------------a-------------------     
Morocco         ----------------------------------------a-------------------      
China-Xinjiang  ----------------------------------------a-------------------     
Fulminant       ----------------------------------------a-------------------      
Pakistan-SAR-55 ----------------------------------------a-------------------      
Burma           ----------------------------------------a-------------------      
Pakistan-Abb-2B ----------------------------------------a-------------------     
Nepal           ----------------------------------------a-------------------      
India-Madras    ---------------------------a------------a-------------------     
T1              ----------------------------------------a-----t------n-m----      
US-1            ----------------------------------------a---x-t------n-m----      
US-2            ----------------------------------------a-----t------n-m----     
94 
 
      506  516    526       536    546       556  
Consensus       SVTLVNVATGAQAVARSLDWSKVTLDGRPLPTIEQYSKSFFVLPLRGKLSFWEAGTTKAG  
Mexico          --------------------------------v-----t---------------------     
ChadT3          -------g------------t---------s--q----t---------------------      
94Egypt         --------------------t---------s--q----t---------------------      
Morocco         --------------------t---------s--q----t---------------------      
China-Xinjiang  --------------------t---------s--q----t---------------------     
Fulminant       --------------------t---------s--q----t---------------------     
Pakistan-SAR-55 --------------------t---------s--q----t---------------------      
Burma           --------------------t---------s--q----t---------------------      
Pakistan-Abb-2B --------------------t---------s--q----t---------------------      
Nepal           --------------------t---------s--q----t---------------------     
India-Madras    --------------------t---------s--q----t---------------------      
T1              t--f--------g-s---------------t--q----t-y-------------------      
US-1            t-----------------------------t--q----k-y-------------------      
US-2            t-----------------------------t--q----t-y-------------------     
 
 
      566       576   585 
Consensus       YPYNYNTTASDQILIENAAGHRVSISTYT                
Mexico          -----------------------a-----                
ChadT3          ------------l----v-----a-----                
94Egypt         ------------l-----t----a-----                
Morocco         ------------l-v--------a-----                
China-Xinjiang  ------------l-v--------a-----                
Fulminant       ------------l----------a-----                
Pakistan-SAR-55 ------------l-v--------a-----                
Burma           ------------l-v--------a-----                
Pakistan-Abb-2B ------------l-v--------a-----                
Nepal           ----------g-l-v--------a-----                
India-Madras    ------------l-v--------a-----                
T1              -----------------------c-----                
US-1            -----------------------a-----                
US-2            -----------------------a-----         
Figure 4.13 Amino acid sequence alignment of the 95-Namibian HEV consensus 
sequence against other global sequences, from position 1,307 to 1,757 of the ORF2 
region. The dashes represent regions of homology with the 95-Namibian consensus 
sequence.  
Most change was synonymous and the Namibian consensus sequence shared an amino 
acid identity of 96.6 % with the Mexican isolate and 94.0-94.6 % with other African 
isolates (Table 4.4).   
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The Namibian amino acid consensus sequence was also compared to the deduced amino 
acid sequences of 83-Namibia and 97/98-Nigerian isolates over a 180 bp region where 
the sequences overlap (Figure 4.14). The alignment confirmed that the 83-Namibia 
sequence belong to genotype I, with its substitutions similar to other genotype I isolates. 
The Nigerian sequences were identical to the 95-Namibian consensus sequence over this 
region except for one amino acid change at residue 580 (‘S’ to ‘A’) which differentiated 
them from the 95-Namibian sequence within genotype II.  
 
      536       546    556       566    576      585 
Consensus       PTIEQYSKSFFVLPLRGKLSFWEAGTTKAGYPYNYNTTASDQILIENAAGHRVSISTYT  
Nigeria-1       -----------------------------------------------------a-----      
Nigeria-9       -----------------------------------------------------a-----     
Mexico          --v-----t--------------------------------------------a-----      
ChadT3          s--q----t---------------------------------l----v-----a-----      
83Namibia       s--q----t---------------------------------l----------a-----      
94Egypt         s--q----t---------------------------------l-----t----a-----      
Morocco         s--q----t---------------------------------l-v--------a-----      
China-Xinjiang  s--q----t---------------------------------l-v--------a-----      
Fulminant       s--q----t---------------------------------l----------a-----      
Pakistan-SAR-55 s--q----t---------------------------------l-v--------a-----      
Burma           s--q----t---------------------------------l-v--------a-----      
Pakistan-Abb-2B s--q----t---------------------------------l-v--------a-----      
Nepal           s--q----t-------------------------------g-l-v--------a-----      
India-Madras    s--q----t---------------------------------l-v--------a-----      
T1              t--q----t-y------------------------------------------c-----      
US-1            t--q----k-y------------------------------------------a-----      
US-2            t--q----t-y------------------------------------------a-----      
Figure 4.14 Amino acid sequence alignment of the 95-Namibian HEV consensus 
sequence against other global sequences, including 83-Namibian and 97/98-Nigerian 
amino acid sequences, from position 1,577 to 1,756 of the ORF2 region. The dashes 
represent regions of homology with the 95-Namibian consensus sequence.  
The 95-Namibian consensus sequence was observed to be more similar to the Nigerian 
isolates (98.3 % amino acid identity) than to the Mexican isolate (94.9 % amino acid 
identity) within genotype II and only 91.5 % identical to the 83-Namibian isolate in 
genotype I (Table 4.5).  
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 CHAPTER 5: DISCUSSION AND CONCLUSION 
 
 
A significant proportion of acute viral hepatitis occurring in young to middle-aged adults 
in Africa, Asia and the Indian subcontinent is caused by hepatitis E virus (Bradley, 
1994). Hepatitis E has major health implications in these countries and outbreaks with 
many thousands of cases are on record. The disease has been shown to occur in both 
epidemic and sporadic endemic forms and is primarily associated with the ingestion of 
faecally contaminated drinking water.  
 
Concern about the disease in South Africa is supported by evidence of typical outbreaks 
with clinical cases in neighbouring countries such as Namibia and Botswana (He et al., 
2000; Byskov et al., 1989). Whilst the virus has been characterized from many regions in 
the world, as well as in Africa, only one outbreak has been definitively described from 
southern Africa (He et al., 2000). Prevalence studies based on serological assessment 
from different populations have suggested activity by this agent in South Africa (Grabow 
et al., 1996; Tucker et al., 1996). Progress in research on the epidemiology of hepatitis E 
is awaited worldwide and this is particularly important in countries such as South Africa; 
where the prevalence of the virus has been shown to be intermediately endemic but at the 
same time conditions exist in many communities which are ideally suited for outbreaks 
of the disease. Reasons for a relatively low incidence of clinical cases and outbreaks in 
certain parts of the world, despite the presence of the virus, are not yet fully understood.  
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The aim of this study was to retrospectively characterize hepatitis E virus from stored 
specimens collected during two hepatitis outbreaks, one which occurred in 1983, in 
Maun, Botswana and the other one which occurred in 1995, in Rundu, Namibia. Methods 
that were developed included extraction of the viral RNA from the clinical specimens, 
and nested RT-PCR to amplify the viral nucleic acid for sequence analysis and 
subsequent phylogenetic analysis. Two different regions of the HEV genome were 
explored. The first region spans 559 bp of the polymerase (RdRp) region within ORF1 
and the second region spans 728 bp towards the carboxy terminal (3’) end of the genome 
in ORF2. The ORF1 region was the first region to be targeted for RNA amplification 
because a plasmid DNA with an HEV ORF1 insert was available as a positive control for 
optimizing the PCR amplification method. The ORF2 region was then targeted for RNA 
amplification since it contains a highly immunogenic epitope (Reyes et al., 1993) and 
most of the published HEV sequences from Africa are based on the ORF2 region; this 
allowed for a meaningful comparative analysis.  
 
Several methods have been used in the past for extraction of HEV RNA from clinical 
specimens prior to RT-PCR. These include the use of glass powder to bind the nucleic 
acid nonspecifically after the disruption of the virus (Mc Caustland et al., 1991), and 
conventional RNA separation by using acid guanidium isothiocyanate-phenol-chloroform 
extraction (Ray et al., 1991). In this study microspin technology was applied (section 
3.6.2) in which the virus is first lysed and the lysate in then passed through a silica-based 
membrane which selectively binds nucleic acid, which is then eluted by passing a small 
volume of buffer through it (Aggarwal et al., 1998). 
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A nested PCR method was developed for amplification of the ORF1 region of HEV 
(section 3.7), initially using an HEV insert from amplified plasmid DNA. Another region 
of the HEV genome, towards the carboxy terminal end of ORF2, was the second region 
targeted for PCR amplification. The ORF2 region is a well studied region of HEV and 
especially in Africa, there is a sufficient number of publications which allowed for a 
more complete comparison of our 1995 Namibian sequences to other African isolates. An 
optimum nested RT-PCR was developed, in this study, for RNA amplification of the 3’-
end of ORF2. Briefly, the specimens were ultracentrifuged at 4 °C with a speed of 23,000 
rpm for one hour (section 3.6.1). RNA was extracted from the pellet by use of the High 
Pure Viral RNA Kit and/or QIAamp Viral Isolation Kit (section 3.6.2). Ten microliters of 
RNA was then mixed together with the Supertherm DNA polymerase enzyme, 1.5 mM 
MgCl2 ion concentration in the 10X Supertherm PCR reaction buffer, AMV RT, RNASin 
and ORF2 primers and the RNA was amplified with the GeneAmp thermal cycler at an 
annealing temperature of 48 °C (section 3.7.2) The ORF2 RT-PCR method was able to 
amplify and produce PCR positive results from the 1995 Namibia specimens. The PCR 
products were then sequenced with the ABI Prism dRhodamine Terminator Cycle 
Sequencing Ready Reaction Kit (section 3.8).  
 
The ORF2 region was again targeted for RNA amplification of the Botswana specimens 
and none of the specimens yielded amplicons even after optimizing the PCR using 
different polymerase enzymes and kits recommended for degraded RNA specimens 
(section 3.7.3). The Botswana specimens were collected in the year 1983 and were stored 
at -70 °C for more than 15 years (before they were used in this study) instead of being 
stored in liquid nitrogen gas, which is ideal for storage of RNA viruses especially over a 
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long period of time (Chobe et al., 1997). Therefore, it was concluded that the nucleic acid 
within specimens was highly degraded (Ray et al., 1991). 
 
Neither PCR was as robust as we would have liked and amplified only a small proportion 
of the clinical specimens (section 4.2.2.1 and 4.2.2.2). This might have been due to 
repeated freezing and thawing of the specimens which can lead to the degradation of 
HEV and the loss of its nucleic acid integrity, and in turn cause difficulties in 
amplification (Ray et al., 1991; Chobe et al., 1997).  
 
In addition, difficulties in PCR amplification of both ORF1 and 2 targeted regions, from 
clinical samples, might have been due to the short duration of HEV RNA in serum (Qi et 
al., 1995). HEV RNA and viral antigens occur in serum from late incubation period to 
early acute phase of the disease. Viremia in HEV infected persons is usually short-lived, 
often peaking and waning before the clinical signs of infection are apparent (Yarbough, 
1999; Lin et al., 2000) and this relates to the timing of virus excretion in faeces (Ray et 
al., 1991; Aubry et al., 1997). The difference between the levels and timing of HAV and 
HEV nucleic acid recovery may be related to a difference in the level of infectious 
particles of HEV found in faeces and blood during infection (Clayson et al., 1995; 
Purcell, 1996; Divizia et al., 1999; Christensen et al., 2002). Animal studies suggest that 
clinical hepatitis E is dose-dependent, that is, for HEV a threshold dose of virus exists 
below which clinical disease does not occur but infection does (Tsarev et al., 1994b, 
Christensen et al, 2002). In other studies no virus was detected in faecal samples by using 
either IEM (Ticehurst et al., 1992) or RT-PCR (Widdowson et al., 2003) and this can be 
due to metabolites and other biological substances interfering with the reactions 
(Turkoglu et al., 1996). One other possible factor contributing to the difficulties in 
amplifying viral sequences is the fact that variation of nucleotide sequence in the primer 
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regions among different HEV strains can be as high as 28 % (Huang et al., 1995; Lin et 
al., 2000). These and other factors such as 5’ and 3’-RNA secondary folding (Huang et 
al., 1992; Agrawal et al., 2001) which could prevent primer binding and result in poor 
cDNA yields, may explain why HEV has never before been isolated from South Africa 
even though antibody based studies appear to indicate the existence of this virus in the 
country [Grabow et al., 1994 and 1996; Tucker et al., 1996; Tucker, personal 
communication]. 
 
Despite the problems encountered, sequence analysis of the PCR fragments obtained did 
allow adequate molecular characterization of the HEV strain responsible for the 1995 
Rundu, Namibia outbreak. Phylogenetic analysis of the carboxy terminal end of ORF2 
region revealed the conventional four genetic clusters consistent with previous findings 
(Tsarev et al., 1999; He et al., 2000; Worm et al., 2000; Schlauder and Mushahwar, 
2001; Widdowson et al., 2003). The ORF2 analysis clearly distinguishes between the 
strains of HEV responsible for the 1995 Namibian outbreak and other reported African 
outbreaks. Genotype I produced a clear division between the Asian isolates and the 
African isolates from Morocco, Chad, Egypt and Namibia-83. These African isolates 
clustered together and away from the Asian isolates (Figure 4.9 and Figure 4.11). The 
1995 Namibian sequences, however, clustered into genotype II together with the 
Mexican isolate with a bootstrap value of a 100 (Figure 4.9) and the Nigerian isolates 
with a bootstrap value of 84 (Figure 4.11), both of which represent statistically 
significant groupings (Muerhoff et al., 1997). This was confirmed by the histogram 
constructed from the 451 bp target region of ORF2 (Figure 4.12). The three peaks of the 
histogram indicate that isolates within the same subgenotype are less than 4 % different 
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from one another, genotypic groups differ by greater than 18 % and subgenotypes are 
defined between these two values.       
The phylogenetic clustering of ORF2 was also confirmed by amino acid analysis based 
on the 451 bp target region. Unique, definitive amino acids common to the 1995 
Namibian subgroup were observed at residues 477 (‘A’ to ‘G’), 535 (‘T’ to ‘S’) and 580 
(‘A’ to ‘S’), and those common to both the 1995 Namibian and the Mexican isolates 
were observed at residues 517 (‘T’ to ‘S’), 527 (‘S’ to ‘P’) and 530 (‘Q’ to ‘E’; Figure 
4.13). Amino acid changes shared by genotype II isolates but not unique to this group 
were observed at residues 569 (‘L’ to ‘I’) and 571 (‘V’ to ‘I’). The Mexican subgroup of 
genotype II is defined by unique amino acid changes at residues 494 (‘V’ to ‘I’) and 529 
(‘I’ to ‘V’). Most change was synonymous and the Namibian consensus sequence shared 
an amino acid identity of 96.6 % with the Mexican isolate and 94.0-94.6 % with other 
African isolates (Table 4.4). The same phylogenetic clustering was observed when the 
1995 Namibian consensus amino acid sequence was compared with the 1983 Namibian 
and the Nigerian amino acid sequences (tree not shown but distance matrix shown in 
Table 4.5). The amino acid alignment in Figure 4.14 also confirmed that the 1983 
Namibian sequence cluster into genotype I and is different from the 1995 Namibian and 
Nigerian isolates.   
 
The Namibia-83 study provided the first published HEV sequence data from southern 
Africa. These isolates were reported to cluster into genotype I (He et al., 2000). This is 
interesting since the 1983 and 1995 Namibian outbreaks both occurred in the Rundu area 
of Namibia. Co-circulating strains within the same country have been reported 
previously. For example, the 1987 Pakistan-Sar55 isolate clustered with other Asian 
isolates in subgenotype I-1a while the 1988 Pakistan-Abb2B isolate clustered with 
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Burmese isolates in subgenotype I-1b (van Cyuck-Gandré et al., 2000).  
 
 
Thus, by successfully amplifying, sequencing and analyzing four representative HEV 
isolates from a non-A non-B hepatitis outbreak in Rundu, Namibia, in 1995 we are able 
to confirm that the agent was indeed HEV, as suspected from the results of the 
serological assays at the time. Furthermore we are able to report the presence of a second 
unique HEV strain in southern Africa, indicating that HEV genotypes may be more 
widely distributed than previously thought. 
 
ELISAs based on recombinant antigens and synthetic peptides have been commercially 
available for detection of present and past HEV infection for some years now. Studies 
using these assays have intimated for almost a decade that healthy populations within 
certain regions of South Africa have HEV antibody. Since HEV outbreaks have now 
been confirmed within the borders of at least one of South Africa’s neighbours, Namibia 
1983 (He et al., 2000) and Namibia 1995 (this study) as well as being strongly suspected 
in Botswana in 1985, travel between other African countries and South Africa could, and 
probably has, introduced asymptomatic and symptomatic sporadic HEV disease into this 
country. Not much is known about the survival of the virus in food and water, both 
implicated in viral transmission, nor the features of the virus or its disease outcome 
which enable it to cause extensive outbreaks under suitable conditions nor indeed the 
reasons for the apparent geographic restriction of outbreaks. In the past warnings have 
been issued to health care personnel to consider hepatitis E as a possible agent in cases of 
hepatitis in travelers but usually this has been restricted to those returning from Asia, and 
countries such as India in particular. This is even more critical in the case of pregnant 
women where disease outcome can be severe. The availability of a nucleic acid test 
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(NAT) for HEV will enable a more routine inclusion of HEV in hepatitis studies 
especially in cases of NANBNC hepatitis. The sensitivity and robustness of NAT has 
recently been significantly improved by “state of the art” methodologies and 
technologies. Two of the most  important of these are based on the MagNa Pure LC 
instrument which robotically performs ultra-pure nucleic acid extraction and sets up 
reaction mixtures for real-time PCR using the LightCycler instrument (both from Roche 
Diagnostics Corporation, Mannheim, Germany). A method employing the real-time 
quantitative PCR with SYBR-green (ds DNA-binding dye) using the LightCycler 
instrument which can detect 10 copies of HEV cDNA fragment per reaction tube from 
human faecal samples after only 3 hours was recently published (Orru et al., 2004). The 
method demonstrated a high linear dynamic range of quantification  from 10 to 106 
molecules of cDNA/reaction with good correlation (r = -1.00). Should our methods and 
those of others become optimized in this way they will facilitate efficient diagnostic 
testing for HEV and open the door for meaningful surveillance studies for HEV in this 
part of the world. Adequate surveillance and rapid, sensitive diagnosis are particularly 
important since strategies aimed at disease prevention are the only methods for disease 
control since to date no vaccine or therapy is available. 
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APPENDIX A: COMPOSITION OF BUFFERS, MEDIA AND GELS  
 
 
1. Reagents for transformation 
 
 1.1 SOC medium: 
Bacto-tryptone 10.0 g 
Bacto-yeast extract 2.5 g 
NaCl 0.25 g 
250 mM KCL 10.0 ml 
 
Adjust the pH of the mixture to 7.0 with 5 N NaOH (~0.2 ml), make up to 500 ml with 
distilled water and autoclave for 15 minutes at 121 °C. Allow the mixture to cool to 60 °
C and add 5.0 ml 2.0 M MgCl2 (19 g MgCl2 in 100 ml distilled water) autoclaved as 
above. Add 20 ml 1.0 M glucose (18 g in 100 ml distilled water) to the mixture, that is, 
after the glucose has dissolved make up to 100 ml with distilled water. Filter the 
complete medium through a 0.2 µm filter unit. 
 
 1.2 LB agar plates:  
LB agar (Lennox L agar)    6.3 g 
 
Make up to 200 ml with distilled water and autoclave for 15 minutes at 121 °C. Allow it 
to cool to 60 °C and then add 1.0 ml of 10 mg/ml kanamycin before pouring the plates. 
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 1.3 LB growth medium:  
LB broth base (Lennox L broth base)   20.0 g 
 
Make up to 1000 ml with distilled water and autoclave for 15 minutes at 121 ºC. Allow it 
to cool to room temperature and then add 1 ml of 10 mg/ml kanamycin. 
 
2. Reagents for agarose gel electrophoresis 
 
 2.1 10X TBE stock buffer: 
 
Tris-HCL 108.0 g 
Boric acid 55.0 g 
0.5 M EDTA 40.0 ml 
 
Make up to 1000 ml with distilled water. Dilute 1:10 for 1X TBE and 1:20 for 0.5X TBE 
running buffer. 
 
 2.2 1 % agarose gel: 
One gram of molecular grade agarose D-1 LE in 100 ml 1X TBE. Heat in microwave 
until dissolved. Allow to cool to room temperature and add 5.0 µl of 10 mg/ml ethidium 
bromide (EthBr) before pouring the gel.  
 
 2.3 2.5 % metaphor agarose gel: 
Metaphore agarose 2.5 g in 100 ml 1X TBE. Mix and leave for 10 minutes to hydrate the 
agarose. Heat in microwave until the solution nears boiling. Cool for 30 seconds, swirl 
and repeat the heating, cooling and swirling until the solution is dissolved. Pour gel and 
leave it to set at room temperature for 15 minutes followed by 30 minutes at 4 °C.  
108 
 
     Appendix A 
 
3. Reagents for clarifying stool samples 
 
 3.1 Gelatin buffered saline (GBS) 10X in 5 liters: 
NaCl   403.75 g 
Na2HPO4.12H20   120.0 g 
KH2PO4   22.5 g 
Phenol red 0.4%   250.0 ml 
Hot water   5000 ml 
 
Sterilize the complete mixture by filtration. 
 
 3.2 0.5 % GBS in 5 liters:  
GBS 10X    500 ml 
Water    4000 ml 
Gelatin (Bacto gelatin)    25.0 g 
Water   5000 ml 
 
Add evaporation water 180 ml/5 L for autoclaving. 
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4. Reagents for resuspending viral RNA 
 
 4.1 Dulbecco buffer 10X Mg++ free in 1 liter: 
 
NaCl 80.0 g 
KCL 2.0 g 
Na2HPO4 anhydrous 11.5 g 
KH2PO4  2.0 g 
 
Dissolve the chlorides in 500 ml and use hot water to dissolve the phosphates, add 
together and make up to 1 liter. 
 
 4.2 Phosphate buffered saline (PBS) Ca++ Mg++ free in 1 liter: 
Dulbecco 10X Mg++ free 100 ml 
 
Add water up to 1000 ml, adjust pH to 7.4 and sterilize by filtration.  
 
5. In-house PCR reaction buffers 
 
 5.1 10X in-house buffer with 10 mM MgCl2: 
1 M Tris pH 8.8    100 µl   
2.5 M KCL  200 µl     
1 M MgCl2 10 µl  
5 % Gelatin 20 µl 
Triton X-100 10 µl 
Water 655 µl  
Mix and make 100 µl aliquots in microcentrifuge tubes and store at 4 °C. 
110 
      
     Appendix A 
 
 5.2 10X in-house buffer with 15 mM MgCl2: 
1 M Tris pH 8.8    100 µl   
2.5 M KCL  200 µl     
1 M MgCl2 15 µl  
5 % Gelatin 20 µl 
Triton X-100  10 µl 
Water  655 µl  
 
Mix and make 100 µl aliquots in microcentrifuge tubes and store at 4 °C. 
 
 5.3 10X in-house buffer with 20 mM MgCl2: 
1 M Tris pH 8.8    100 µl   
2.5 M KCL  200 µl     
1 M MgCl2 20 µl  
5 % Gelatin 20 µl 
Triton X-100 10 µl 
Water 655 µl  
 
Mix and make 100 µl aliquots in microcentrifuge tubes and store at 4 °C. 
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 5.4 10X in-house buffer with 25 mM MgCl2: 
1 M Tris pH 8.8    100 µl   
2.5 M KCL  200 µl     
1 M MgCl2 25 µl  
Water 675 µl   
 
Mix and make 100 µl aliquots in microcentrifuge tubes and store at 4 °C. 
 
6. Reagents for sequencing  
 6.1 Sequencing gel 
  6.1.1 5 % Gelmix 50 ml: 
Urea  19.0 g 
Baxter water  24.5 ml 
10X TBE  7.5 ml 
50 % Long ranger  5.0 ml 
 
Mix for 30 minutes to dissolve and filter through Millex HV filter. 
 
 6.2 10 % Ammonium persulphate: 
Ammonium persulphate  0.5 g 
Baxter water  4.5 ml 
 
Mix until it is dissolved, filter through a 0.45 µm filter unit, aliqout into 300 µl amounts 
and store at -20 °C. Thaw at room temperature before use. 
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 6.3 Gelmix to polymerise 50 ml: 
Temed  25.0 µl 
10 % Ammonium persulphate  250 µl 
 
Mix gently without making bubbles and leave for 2.5 hours before use.  
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APPENDIX B: LIST OF SUPPLIERS 
 
ABI PRISM 377 DNA Sequencer  Perkin Elmer Corporation, California, USA 
Abbott HEV EIA Kit    Abbott Diagnostika, Wiesbaden-Delkenheim, Germany 
Ammonium persulphate   Amersham Pharmacia Biotech Ltd, Buckinghamshire, 
UK 
AMV     Roche Diagnostics Corporation, Mannheim, Germany 
ALFexpressTM DNA Sequencer   Amersham Pharmacia Biotech Ltd, Buckinghamshire, 
UK 
Applicator sticks    LASEC, Laboratory and Scientific Equipment, South      
Africa 
Bacto-tryptone    Unipath Ltd, UK 
Bacto-yeast extract   DIFCO Laboratories, USA 
Baxter water    Adcock Ingram, Sterilab Services, South Africa 
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APPENDIX C: APPROVAL FOR UNDERTAKING RESEARCH  
     PROJECT  
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